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ABSTRACT
Tensin is a large “docking” protein found in the adhesive junctions of animal cells
and recruited early in the development of cell-substrate contacts. There it binds to the
cytoplasmic domain of integrin ft and caps the barbed ends of filamentous actin. This
forms a rational basis for its implication in a direct role in the mechanics of membranecytoskeleton interactions. Tensin provides a physical link between the actin cytoskeleton,
integrins, and other proteins at the cell-substrate contacts. Its overall biochemical
properties are a function of its domain composition and architecture, i.e., the domains that
are present and their relative positions in the molecule, and specific details of amino acid
sequence and post-translational modifications. Tensin can be used as an investigative tool
to help explain the physiology of cell-substrate contacts at the molecular scale. The C2
domain indicated to be present at the N-terminus of tensin, along with the phosphatase
domain, bears a close homology to PTEN (Phosphatase and Tensin Homolog), a well
known tumor suppressor. The main research objective was to study the structural features
of the C2 domain of human tensin as well as to investigate its thermal stability.
For this purpose, the C2 domain gene, after being synthesized by Polymerase
Chain Reaction, was cloned into the engineered pET-14b vector that would also encode a
hexa-Histidine tag. The C2 domain gene was then overexpressed in E.coli and the
inclusion bodies thus formed were solubilized and lysed. Ni-NTA metal affinity
chromatography was performed to obtain the purified C2 domain. Circular dichroism was

iii
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used for the initial study of the structural features of the purified C2 domain. After
determining that the purified C2 domain was unstable, refolding attempts were done.
Later studies of the domain by circular dichroism in the far-UV and near-UV
wavelengths indicated that the domain unfolded gradually with increasing amounts of the
denaturant GuHCl and also that it retained some amount of tertiary structure prior to
denaturation.
The absence of an endothermic peak in the Differential Scanning Calorimetry
experiments only suggests the need for further extensive refolding methods not attempted
in this work and might also indicate the need for the presence of a phosphatase domain at
its N-terminus for thermodynamic stability. The results of this work suggest the presence
of a C2 domain in human tensin, which has not been documented previously.
Determination of all the structural and functional characteristics of the C2 domain in the
long run will contribute to the understanding of the role of tensin in tumor suppression
and cell signaling.
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CHAPTER 1
INTRODUCTION
1.1. The Human Genome
Cells are the fundamental working units of every living system. The DNA
sequence within any living organism spells out the exact instructions required to create
that particular organism with its own unique characteristics. The complete set o f DNA
within an organism is termed “genome”, and it varies widely in size from organism to
organism [1]. “Genomics involves using reagents, tools and technologies for the high
throughput sequencing o f DNA and the subsequent storage and annotation of data” [2].
This process focuses on the information of one target molecule, DNA, in the nucleus of
cells. Consequently, there is one genome for each organism. The human genome
comprises approximately of 3 billion chemical bases which includes 20,000-25,000
protein-coding genes. The U.S. Human Genome Project, begun in 1990, had the goals of
identifying all the 20,000-25,000 protein coding genes, determining the sequences of the
3 billion bases that make up the human DNA and hence make them accessible for further
biological studies. Though initially planned to last for 15 years, rapid technological
advances have accelerated the project to be completed within 13 years in the year 2003
[!]•

1
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1.2. What is Proteomics?
Proteomics refers to the large-scale study of proteins, particularly their structures
and functions. The term ‘proteome’ of an organism refers to the entirety of proteins in
existence in that organism throughout its life cycle [3]. Each of the cells present in an
organism contains all the information necessary to make that organism complete.
However, not all the genes are expressed in all the cells. Genes that code for enzymes
essential to basic cellular functions are expressed in virtually all the cells, whereas those
with highly specialized functions are expressed only in specific cell types. Thus, all cells
express genes whose protein products provide essential functions and also those genes
whose protein products provide unique cell-specific functions. Thus, every organism has
one genome, but many proteomes [4]. While the genome is a rather constant entity, the
proteome differs from cell to cell and is dynamic in nature through its biochemical
interactions with the genome and the environment. As such, an organism has radically
different protein expression in different parts of its body, in different stages of its life
cycle and in different environmental conditions. Hence proteomics is considered much
more complicated than genomics [3]. The biochemical context of genomics and
proteomics is depicted in Figure 1.1.
The Human Genome Project also revealed far fewer protein-coding genes in the
human genome than there are proteins in the human proteome. This large increase in
protein diversity is believed due to alternative splicing and post-translational modification
of proteins. The quantity and complexity of the data derived from the sequencing and
mapping o f the human proteome are estimated to be at least three times greater than that

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

involved in the Human Genome Project [3]. The field of proteomics is particularly
important because most diseases are manifested at the level of protein activity. As such, it
seeks to correlate directly the involvement of specific proteins, protein complexes and
their modification status in a given disease state. Such knowledge will provide a fast
track to commercialization and will speed up the identification of new targets that can be
used to diagnose and treat diseases [2].

DNA

Genome
"G enom ics”

mRNA

1

proteins

Proteome
“Proteom ics”

Cell functions
Figure 1.1. Biochemical context of genomics and proteomics [4],

1.3. Tensin in the Context of a Proteome
Tensin is one of the several thousands of proteins that are expressed in animal
cells including H.sapiens. It is a component of cell-substrate contacts with a close
homology to a well established tumor suppressor protein PTEN [38], Since the exact
functions of tensin “modules” or “domains” in humans have not been established, this
current research on the individual domains of tensin will attempt to contribute to the
understanding of the structure and functionality of the protein and might explain its
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predicted role in tumor suppression. Overall the work performed in this project involving
various tools of proteomics will contribute to the understanding of the proteome.

1.4. Overview of the Dissertation
Chapter Two discusses the background information underlying the tensin
research. It talks about cell adhesion in general and introduces tensin as a key component
of focal contacts. The various domains of tensin and their functions are briefly discussed.
The motivation for tensin research is highlighted.
Chapter Three discusses the theory and background information relating to the
procedures involved in the design and synthesis of the C2 domain gene. All the
experimental methods involved in the above procedures including their results and
discussions are also mentioned.
Chapter Four discusses the theory and background information relating to the
procedures involved in the expression, detection and purification of the C2 domain are
briefly discussed. All the experimental methods involved in the above procedures
including their results and discussions are also mentioned.
Chapter Five discusses the theory and background information relating to the
procedures involved in the refolding and biophysical characterization of the C2 domain.
All the experimental methods involved in the above procedures including their results
and discussions are also mentioned.
Chapter Six lists the conclusions derived from the results of the experimental
work performed on the C2 domain of human tensin. It also discusses the future work.
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CHAPTER 2
LITERATURE REVIEW
2.1. Introduction
2.1.1. Cell Adhesion
Cell adhesion plays an important role in the genesis and maintenance o f both
three-dimensional structure and normal function in tissues. The functional units o f cell
adhesion are multiprotein complexes of three general classes of proteins: the cell
adhesion molecules/adhesion receptors, the Extra Cellular Matrix (ECM) proteins, and
the cytoplasmic plaque/peripheral membrane proteins.

Cell adhesion receptors are

typically transmembrane glycoproteins that mediate binding to ECM molecules or to
counter-receptors on other cells. These molecules also determine the specificity of cell
cell or cell-ECM interaction. The ECM proteins are fibrillar providing a complex
structural and functional network that can interact simultaneously with multiple cell
surface receptors. The cytoplasmic plaque/peripheral membrane proteins provide
structural

and functional

linkages between

adhesion receptors and the

actin

microfilaments, microtubules, and intermediate filaments of the cytoskeleton [5, 6]. The
cell adhesion complexes are not static, but rather dynamic and can capture and integrate
signals from the extracellular environment. The functions of these complexes are
regulated precisely by biochemical events within the cell. Adhesion-mediated signaling

5
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influences the cellular processes of gene expression, cell cycle and programmed cell
death [5].
2.1.2. Focal Adhesions
Integrins are a family of transmembrane proteins that link the cytoskeletal
elements at the cytoplasmic face with ECM components. Integrins are heterodimers of a
and j8 subunits that contain a large extracellular domain responsible for ligand binding, a
single membrane-spanning region and a short cytoplasmic domain [7]. Integrin-mediated
cell-ECM adhesion sites are complex specialized structures known as focal contacts or
focal adhesions [8]. At focal adhesions, clusters of integrins bind externally to ECM
proteins and internally to several cytoplasmic proteins that in turn bind to actin filaments
[9, 10] as shown in Figure 2.1.

ACTIN

Bdraoefijtar Matrix

Figure 2.1. Schematic diagram of the molecular architecture of a focal adhesion [10].

Focal adhesions are dynamic and they change in their size and composition as the
cell adhesion progresses. Initially, small freckled structures are formed at the sites of cellto-substratum contact and as the focal contact matures, the actin filaments extend and
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bundle to form prominent stress fibers. At focal adhesions, there is a complex network of
interactions among the specialized cytoplasmic proteins [5]. The cytoskeletal proteins
that directly bind to integrins include talin and a-actinin, which in turn bind to other
proteins including vinculin, paxilin and tensin, ultimately leading to the recruitment of
actin filaments. Some of the key structural proteins involved in focal contacts are
described in Table 2.1.

Table 2.1. Key structural proteins involved in focal contacts.

Protein

Localization

a-Actinin

It is found in Z-discs in
skeletal muscles,
membrane-associated dense
plaques, cytoplasmic dense
bodies of smooth muscle,
and adherens-type junctions
in non-muscle cells [11].

Talin

It is localized to focal
adhesions [14]

Structure/
Orientation
It is a rod-shaped
anti-parallel
homodimer with a
subunit molecular
mass of 104 kDa
[11].

It is a homodimer
of two 270 kDa
polypeptides [15]
and is arranged in
an anti-parallel
orientation.

Binding/ Function
It binds to vinculin [8],
zyxin [12], and the
cytoplasmic domains
of integrin /31, /32, and
/33 subunits [5]. It
associates actin
molecules to focal
adhesions [13].
It binds to actin,
vinculin [16], focal
adhesion kinase (FAK)
[17] and integrin j81,
/33 subunits [8]. It
connects actin
cytoskeleton to focal
adhesions and is also
crucial for the initial
formation of focal
adhesions [14, 15].
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Vinculin

Paxillin

Filamin

Tensin

It is localized to focal
contacts and cell-cell
adherens type junctions [8].

It is a 116 kDa
polypeptide with
globular head and a
rod-like tail region
[20]

Its head region binds
to talin and a-actinin,
while its tail to paxilin
and actin [21, 22].
It binds to
phosphatidylinositol 4,
5-biphosphate (PIP2),
which regulates its
focal contact
formation and stability
[23],

It is localized to the
membrane at focal
adhesions [24, 25]

It is a 68 KDa
protein. The Nterminus has a Src
homology region 3
(SH3) domain and
multiple SH2
binding sites, while
its C-terminus has
four LEM domains
that are involved in
protein-protein
interactions [26].

It binds to FAK [27],
vinculin [28], p47gag<rk
[29], C-terminal Src
Kinase (CSK) [26] and
pp60src [30]. As such it
acts as an adapter
protein involved in
forming multiprotein
complexes.

It is localized into the stress
fibers and dense bodies in
non-muscle cells and Z
bands in both skeletal and
cardiac muscle cells [32],

It is a homodimer
with two
polypeptides
associating only at
the C-terminus,
while the Nterminal ends link
with actin [33].

It is localized to various
adherens junctions and Zlines of skeletal muscle
[35],

It is a 220 kD
protein containing
an actin binding
region [36], PTP
[37], C2 [38], SH2
[39] and PTB [40]
domains.

It associates with the
/32 integrin
cytoplasmic domain
with is important in
spreading and
extension of
lamellopodia during
cell movement and
phagocytosis [34].
It links cytoskeleton to
the plasma membrane,
coordinates cell
attachment and
suppresses cellular
transformation [41]. It
also plays a role in
signal transduction
[39].
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2.1.3. Tensin
Tensin is located at the transmembrane junctions between the ECM and the
cytoskeleton [41-43]. In H. sapiens, tensin contains 1735 amino acid residues [44] and is
encoded by a gene on chromosome 2 at locus q35-36. Tensin is present in at least two
different cell pools, either in the cytoplasm or the focal adhesion complex. The
cytoplasmic tensin can suppress cell migration by inactivating downstream regulators,
and localization of tensin at focal adhesions is insufficient to promote cell motility [45].
Tensin has three signal transduction-related domains: a protein tyrosine phosphatase
(PTP) domain [37], a Src homology 2 (SH2) domain [39], and a phosphotyrosine binding
(PTB) domain [40] as shown in Figure 2.2. The PTP, SH2 and PTB domains are wellknown to be involved in phosphorylation-mediated interactions in related signaling
proteins such as the tumor suppressor PTEN (phosphatase and tensin homolog), Src
family kinases, and She. A C2 domain (similar to the second conserved domain from
protein kinase C) has also been indicated to be present in the protein tensin [38].
Recently, the C2 domains have also been shown to bind phosphorylated peptides
increasing the odds of their involvement in signaling pathways [46, 47]. As such it very
much seems likely that the participation of tensin in membrane-cytoskeleton interactions
will be modulated by signaling involving phosphorylation.
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P h o s p h o r y l-r e c o g n itio n m o d u le s
A c tin -c a p p in g re g io n
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v ----------PTEN-homolog
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^
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Figure 2.2. Domain architecture of tensin. “Y” and “Z” are identified putative domains
(Haynie, D. T, unpublished)
There are three regions in the full-length tensin polypeptide (Haynie,
unpublished): N-terminus, central region, and C-terminus (Figure 2.2). The N-terminus
consists of the PTP and C2 domains. PTP domain is probably inactive because the
essential nucleophilic cysteine is mutated to asparagine [37]. This N-terminal region of
tensin is homologous to auxilin [37], cyclin G-associated serine/threonine kinase (GAK)
[48], and PTEN [38], also known as multiply-mutated in advanced cancers (MMAC) [49]
as shown in Figure 2.3. Torgler et al. have shown that the phosphatase domain of tensin
in Drosophila is required for the localization at muscle attachment sites and Z lines, and
also that the deletion o f the phosphatase and C2 domains completely inactivates the
protein [50]. This region of tensin is also thought responsible for the wing blister
phenotype of certain Drosophila mutants, which also exhibit a reduced hatching rate of
laid eggs [51]. The C2 region of the protein PTEN regulates the tumor suppressor activity
of PTEN [53],
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Figure 2.3. Domain architecture of tensin-like proteins (Haynie, D. T, unpublished).
By in vitro assays, it was determined that the central region of tensin binds to the
barbed ends of filamentous actin (F-actin) (Figure 2.4) and retards the rate of actin
polymerization [53]. Tensin can also crosslink actin filaments [36].

F-actin
SH2 PTB

PTP

C2

integrin
P subunit
a subunit

Figure 2.4. Schematic of the hypothetical model of interaction of tensin with other focal
adhesion components, including the plasma membrane. Integrin interacts with FN in the
ECM and with tensin inside the cell. The F-actin filament bundle will extend into the
cytoplasm (Haynie, D. T, unpublished).

The C-terminal region of tensin contains an SH2 and a PTB domain, both of
which are phosphotyrosine interaction motifs involved in various signal transduction
pathways. Binding o f phosphotyrosine by the SH2 domain may be important for tensin-
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promoted cell migration [45]. The PTB domain of human tensin binds the cytoplasmic
domain of various /3 integrins [53]. So far, three isoforms have been identified for tensin.
They are tensin 1, tensin2, and tensin3; all of them are homologous in their N- and Cterminal domains but divergent in their central regions [54, 55].
Tensin plays a role in wound healing and cell migration as suggested by the delay
in the skeletal muscle regeneration of tensin knock out mice [56]. A study of tensin (-/-)
mice also showed that cellular development was normal for several months, but later
multiple cysts were formed in kidney cells that led to kidney degeneration and caused
renal failure [57]. Tensin is also a substrate of the focal adhesion protease, calpain II,
which is involved in the assembly and disassembly of focal contacts [44]. Tensin is
phosphorylated on serine, threonine, and tyrosine residues [41]. Tyrosine phosphorylation
o f tensin is induced by growth factors such as platelet derived growth factor (PDGF),
thrombin, angiotensin, and oncogenes like v-src or brc/abl. [39, 58].
2.1.3.1. PTP (Protein Tyrosine Phosphatase)
domain
Tyrosine phosphorylation plays a role in communication between and within
cells, maintaining the shape and motility of cells, cellular processes like regulation of
gene transcription, mRNA processing, and transport of molecules in or out of cells. It
also plays an important role in the coordination of these processes among neighboring
cells in embryogenesis, organ development, tissue homeostasis, and the immune system.
Abnormalities in tyrosine phosphorylation play a role in the pathogenesis of numerous
inherited or acquired human diseases from cancer to immune deficiencies [59].
Reversible protein phosphorylation is a common element of intracellular signal
transduction pathways which regulate metabolism, gene expression, cell division and
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differentiation, development, transport, locomotion and learning and memory [60]. The
structural and functional consequences of incorporating a phosphate group into a protein
are diverse, and probably underlie the fundamental role of protein phosphorylation in
cellular regulation [61].
Protein Tyrosine Phosphatases (PTPs) are a family of signal transduction enzymes
that catalyze the removal of phosphate groups from phosphotyrosine containing proteins.
By doing so, they dynamically oppose the action of protein tyrosine kinases (PTKs)
which are key to the phosphorylation of proteins [60, 62],

PTPs are classified as

receptor-like or intracellular based on cellular localization. Receptor-like PTPs contain a
transmembrane domain, an extracellular receptor-like domain, and two intra-cellular PTP
domains. The first intracellular domain generally accounts for most of the catalytic
activity; the function o f the second domain is unknown in most cases. Dual specificity
phosphatases (DSPs) constitute a sub-family o f intracellular PTPs. While PTPs can
dephosphorylate only the tyrosine residues in phosphorylated proteins, DSPs can
dephosphorylate serine, threonine as well as tyrosine residues [56, 58].
A key feature of the members of the PTP family is the active site sequence known
as the PTP signature motif: (H/V)C(X)5R(S/T) [56, 58], The signature motif forms a loop
(called P loop) at the bottom of the active site pocket. The walls of the pocket are made
up of side chain and backbone groups from P loop residues. The signature motifs of PTP
in tensin, PTEN and VHR are shown in Figure 2.5.
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Signature motif : WPD...H|XXGXXRS
WPD...HNKGNRGRI
Tensin:
f e d ...h | k a g k g r s
PTEN:
and...h|regysrs
VHR:
Figure 2.5. Signature motif of PTP in tensin, PTEN, and VHR. Conserved residues are
highlighted in yellow, while the essential nucleophilic cysteine residues are highlighted in
green.

The active site of the PTP domain of tensin is different from the usual signature
motif o f PTPs and DSPs. The essential nucleophilic cysteine is mutated to asparagine.
The probable effect of this might be a loss of catalytic activity in human tensin. However,
an important aspartic acid, which functions as a general acid or base in catalysis, is
conserved in tensin on a flexible loop approximately 30-40 residues towards the Nterminus of the signature motif. The arginine and glycine residues of the signature motif
are also conserved in tensin. Glycine is important for the formation of the turn in the P
loop. This suggests that the basic shape of the binding pocket will not be substantially
different from that in a known PTP and that the PTP domain in tensin will recognize a
phosphorylated chemical group.
The principal structural difference between the tyrosine specific PTPs and the
dual specific PTP VHR is the depth of the active site pocket. The relatively shallow
pocket of VHR can accommodate phosphotyrosine or phosphothreonine; the deeper
pocket of PTP IB can only accommodate phosphotyrosine. The PTP domain of tensin is
distinguished from other PTPs by its lack of catalytic activity [37]. Also, in the C.elegans
variant of tensin, the histidine preceding the cysteine is mutated to phenylalanine. Both
the above mutations are likely to eliminate all phosphatase activity. The PTP domain in
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tensin will presumably protect a phosphorylated chemical group on a binding partner
from the catalytic activity of phosphatase.
The phosphatase domain of PTEN, a known tumor suppressor, can also
dephosphorylate phosphoinositide substrates invitro besides tyrosine-, serine-, and
threonine- phosphorylated peptides. It has an enlarged active site, and it specifically
dephosphorylates phosphatidylinositol (3, 4, 5) - triphosphate (PI(3,4,5)P3), a lipid
second messenger produced by the phosphoinositide 3-kinase (PI3K) and activates
downstream effectors. These effectors include the Akt/PKB kinase that has potent
antiapototic and growth stimulatory effects [38].
2.I.3.2. SH2 (Src Homology 21 domain
SH2 domain is the prototype for protein-protein interaction modules that mediate
the formation of multiprotein complexes during signaling [63, 64]. SH2 domains
specifically function in protein tyrosine kinase (PTK) pathways, due to the dependence of
their binding on tyrosine phosphorylation [65]. SH2 domains represent the largest class
o f known p-Tyr (phosphotyrosine) recognition domains [64], SH2 domains are usually
found in proteins together with other modules, either catalytic domains like phosphatase
domain, or other protein binding modules like SH3, PH, or PTB domains. Hence,
depending on the nature of those other modules, proteins containing SH2 domains can
participate in a wide variety o f intracellular functions [66].
SH2 domains carry out their function by binding with high affinity to
phosphotyrosine containing protein targets in a sequence-specific and largely
phosphorylation-dependent manner. In addition to the p-Tyr residue, each SH2 domain
recognizes several additional flanking residues, usually three to five amino acids C-
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terminal to p-Tyr, thereby acquiring selectivity for specific phosphorylated sites [67]. The
peptide-binding specificity o f large number SH2 domains has been investigated with
libraries of peptides phosphorylated on a tyrosine residue and randomized at the +1, +2
and +3 positions C-terminal to the phosphotyrosine residue. Individual SH2 domains
bind to unique sequences, while many SH2 domains bind to the sequence pYEEI as
shown in Table 2.2.
Table 2.2. SH2 family proteins and their binding partners.
Subgroups of SH2 domain

Amino acid sequence of binding partner

Src, Fyn, Lck, Fgr, Abl, Crk, Nek

pY-hydrophilic-hydrophilic-I/P

P8, phospholipase C-gamma, and SHPTP2

p Y-hydrophobic-X-hydrophobic

Src sub family (Src, Fyn, Lck and Fgr)

pY-E-E-I

In some cases, an SH2 domain can bind to the target protein or ligand in a nonpTyr dependent manner. Such binding could be a property of the SH2 domain in tensin.
Alternatively, the SH2 domain of tensin could possibly interact with a phosphotyrosine
residue in the same tensin molecule (intramolecular association as in Src) or in another
tensin molecule (intermolecular association as in dimerization).
An SH2 domain consists of -100 amino acids with two a-helices and seven /3strands, ordered /3o$/3/3/3/3a/3, with a central anti-parallel /3-sheet flanked by a-helices [68].
The folded structure o f the SH2 domain is of a+/3 class. Each SH2 domain-containing
protein has distinct sites for recognizing p-Tyr and particular amino acid chains.
Recognition also depends on the specific amino acid sequences flanking the
phosphotyrosine in a specific target; indeed, the variability in SH2 domain sequences
provides a structural basis for target selectivity. In many cases when an SH2 domain is
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present, so too is an SH3 domain. The domains are frequently found as repeats in a single
protein sequence, which suggests that the functions of the SH2 and SH3 domains are
inter-related.
SH2 domain covers the region from 1463 to 1557 in tensin at the C-terminus.
SH2 domain of tensin binds to Src, paxillin, p i 30, and other tyrosine-phosphorylated
proteins. The tensin SH2 domain can also interact with certain tyrosine-phosphorylated
proteins, notably PI3K and pl30CAS [69, 70].
2.1.3.3. PTB (Phospho Tyrosine Binding)
domain
The PTB domain plays an important role in protein-protein interactions and signal
transduction [71-73]. The PTB domain was first identified in the signaling proteins She
(Src homolog-collagen homolog) and IRS-1 (Insulin receptor substrate-1) as an
alternative to the SH2 domain for phosphotyrosine recognition [72, 74, 75]. In contrast to
SH2 domains which bind exclusively to peptides containing phosphotyrosine, PTB
domains bind to phosphotyrosine sites on activated tyrosine kinases and are involved in
diverse cellular functions. She binds to pTyr sites on growth-factor activated tyrosine
kinases and oncogene products. The PTB domains of She and IRS-1 bind to other
proteins or ligands containing NPXpY motif, where ‘pY’ is phosphorylated tyrosine and
‘X’ any amino acid [76].
The PTB domain o f tensin seems to prefer non-phosphorylated substrate. Tensin
is co-localized with integrins in the absence of extracellular ligand binding, which
suggests that it associates with integrins before it bonds to ligands. Moreover, tensin is
phosphorylated in response to the integrin adhesion, suggesting that it is a part of the
down stream-signaling pathway. The PTB domain of tensin binds strongly to the
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cytoplasmic tails of integrin jS3, (35 and (37 but binds weakly to /SI A, which implicates the
tendency o f the domain to bind in a phosphorylation independent manner. The potential
binding partners of the PTB domain are PI3K, pl30CAS [69].
In other proteins, the PTB domains have been found to participate in
phosphotyrosine-independent interactions. For example, members o f the X I 1 family of
proteins contain a PTB domain that binds peptides in a phosphotyrosine-independent
fashion (Table 2.3).

Table 2.3. PTB family proteins and their ligand-binding partners. Residues in bold italics
are known to be involved in binding or are conserved among PTB domain binding targets
[77].
Proteins with PTB domain

Binding Partner

She
IRS-1
NUMB

EGFR
IR
LNX
NAX
Peptide Screen
APP

X ll

Amino acid sequence of the
peptide binding site
SLD7VPDFQQDF
LYAA SSN P EYLA S
GLDAPAFTSSV
GFS7VMS.FEDFP
GFSAMSFEDFP
GYENPTYKFFE

Sequence analysis and experimental studies on integrin and tensin show that the
interaction o f integrin with tensin takes place through the PTB domain of tensin. The
PTB domain o f tensin thus plays a key role in the function of tensin as an adaptor protein
and as a connector between FA molecules and intracellular signaling. Much direct and
indirect evidence has shown that tensin acts as an adaptor protein for integrin and is a
required component of FAs.
2.1.4. C2 Domain
C2 domains were first identified in classical protein kinases C (PKCs) [78] as
calcium-dependent lipid binding modules. They are intracellular and are present in
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numerous proteins with functions ranging from signal transduction to vesicular
trafficking [79],

C2 domains are categorized into calcium-dependent or calcium-

independent forms by the way they interact with phospholipids. In PLC51, PKC, and
CPLA2 , the C2-domains are of type II topology, and play a regulatory role by mediating
the enzymes to bind to phospholipids in a calcium dependent manner. On the other hand,
C2 domains in synaptotagmin I, rabphilin-3, RIM, and Muncl3, are of type I topology,
and bind Ca+2 through three loops implicated in mediating association with the plasma
membrane. Proteins exhibiting the type II topology are involved in the generation of
lipid second messengers (e.g. cPLA2, PLCs, and PI3K), protein phosphorylation,
activation o f GTPases (e.g. Ras-GAP), and ubiquitin ligation (e.g. Nedd4) [79].
The C2 domain of PTEN folds into a /3-sandwich structure consisting of two
antiparallel /3 sheets with two short a helices intervening between the strands (as in
Figure 2. 6). This (3 sandwich is identical to type II topology of the C2 fold as in PLC51,
PKC<5, and CPLA2 . The C2 domain of PTEN also lacks canonical Ca+2 ligands and is
therefore unlikely to bind Ca+2.
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Figure 2.6. Ribbon diagram of the structure of the C2 domain in PTEN [38].

PTEN has a calcium-binding region 3 (CBR3) loop that has the same structure as
in the Ca2+-dependent C2 domains [38]. This loop may be important for membrane
binding. The CBR3 loop of PTEN has a positive charge at neutral pH, resulting from
Lys-260, Lys-263, Lys-266, Lys-267, Lys-269, and the partially buried His-259-Asp-268
pair. This situation resembles the positive charge on the Ca2+-dependent C2 domains that
results from the binding of Ca2+ to the CBR3 loops. The positive charge on the C2
domains has been implicated in their affinity for phosphoryl groups of phospholipids.
The PTEN C2 domain also contains two solvent-exposed hydrophobic residues,
Met-264 and Leu-265, both at the tip of the CBR3 loop. About half o f the known C2
domains contain at least one hydrophobic residue at this position. Experimental results
suggest that these hydrophobic residues may enable synaptotagmin to insert into a lipid
bilayer. The PTEN C2 domain has an additional patch of basic residues on the adjacent
Cg!2 helix, resulting from the solvent-exposed Lys-327, Lys-330, Lys-332, and Arg-335.
This is a position similar to helix of CPLA2 that has been implicated in membrane
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binding. The PTEN C2 domain may not only help recruit PTEN to the membrane, but it
may also serve to position and orient the catalytic domain optimally with respect to the
membrane-bound substrate.
A molecular model of PTP-C2 domain interface in PTEN is shown in Figure 2.7.
The conserved Arg and the two Tyr residues of the PSXXRY(L/V)XY motif shown in
ball-and-stick representation, point into the domain interface. Also, the conserved Asp
residue in the (L/V)XGD(I/V)X(L/V) motif is immediately in front of the left most balland-stick Tyr within the domain interface. Since these hydrophobic residues pack
together within the domain interface, additional stability is induced in the C2 domain of
PTEN.

Figure 2.7. PTP-C2 domain interface in PTEN. Part of the PTP domain is at the top of
the figure, part o f the C2 domain is at the bottom. Secondary structures are shown as
ribbons, a helices in red, (3 strands in cyan, and turns in green. (Haynie, D. T,
unpublished)
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The homology o f the PTEN phosphatase domain has with tensin and auxilin, both
of which lack key phosphatase active site residues, maps primarily to the hydrophobic
core and to residues on the surface of the po6 helix as mentioned earlier. Since these
helix residues pack onto the C2 domain, tensin, auxilin, and GAK may also contain a C2
domain [38]. The sequence alignment of various C2-like regions in different proteins is
shown in Figure 2.7. 1D5RA and NP 072174 are the C2 domain sequences of human
PTEN and tensin respectively. Though the sequence heterogeneity is generally high,
relatedness is discemable.
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Figure 2.8. Sequence alignments of various C2-like regions. lD5RA=human PTEN,
CAD60625=zebra fish PTEN-like protein, AAF23237=fruit fly PTEN, DictyPTEN=
slime mold PTEN, NP_174461=thale cress (plant) actin binding protein, NP_037447=
human transmembrane PTEN isoform alpha, NP_072174=human tensin, rat= rat GAK
(Cyclin G-associated serine/threonine kinase), auxilin= cow auxilin and ebiP5528=thale
cress (plant) auxilin-like protein. (Haynie, D. T, unpublished)
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Figure 2.9 shows the ribbon diagram of the C2 domain of PTEN and tensin
colored according to the secondary structure. Overall, the structures are quite similar.

Tensin

PTEN

Figure 2.9. Ribbon diagrams of the C2 domain of PTEN and tensin. Red: a-helix; blue: /3
sheets; green: turns and white: irregular structure. (Haynie, D. T, unpublished)

A comparison of structural features is made in Table 2.4. The backbone RMSD is
as low as 0.5 A. Ratio of SAS/TMS is similar in both cases, c. 40%. The number of
hydrogen bonds per amino acid is close to 1. All the analyses are close to the average
protein structure characterization data.

Table 2.4. Structural comparison of C2 domain of PTEN and tensin models (Haynie, D.
T, unpublished).
PTEN
H-bonds/amino acid
Solvent accessible surface (SAS)
Total molecular surface (TMS)
SAS/TMS
RMSD (backbone)

TENSIN

0.82
0.98
8,804 A1 10,052 Az
24, 153 A1 25, 067 A1
36.4%
40.1%
-0.5 A
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The computational modeling results as shown in Table 2.4, strongly lead to the
hypothesis that a C2 domain similar to that of a PTEN is present in tensin.

2.2. Research Objective
To prove the hypothesis that a C2 domain similar to that of PTEN is present in
tensin, it is important to determine the structural features and thermodynamic stability of
the C2 domain o f tensin. Hence the main research objective of the current project was to
determine the structural features of the C2 domain of human tensin as well as to
investigate its thermal stability.
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CHAPTER 3
DESIGN, SYNTHESIS AND CLONING
OF THE C2 DOMAIN GENE
3.1. Design and Synthesis of the C2 Domain Gene
3.1.1. Introduction
This section consists of various subtopics covering the theory and background
relating to the procedures involved in the design and synthesis of the C2 domain gene.
3.1.1.1. The genetic code
Genetic information is specified by the order of nitrogenous bases viz adenine
(A), cytosine (C), guanine (G) and thymine (T) that make up the deoxyribonucleic acid
(DNA) molecule. A DNA molecule consists of two long polynucleotide chains composed
of four types of nucleotide subunits. These nucleotides are composed of five-carbon
deoxyribose to which is attached one or more phosphate groups and a nitrogenous base
(A, G, C or T). The nucleotides are covalently linked together in a chain through the
sugars and phosphates, which forms a sugar-phosphate backbone. The three-dimensional
structure of DNA is the double helix, which is formed by the chemical and structural
features o f its two polynucleotide chains [80]. Because these two chains are held together
by hydrogen bonding between the bases on the different strands, all the bases are on the
inside o f the double helix, and the sugar-phosphate backbones are on the outside as
shown in Figure 3.1A. A always pairs with T, and G with C as shown in Figure 3.IB.
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RNA is also a linear polymer like DNA except that it has the base thymine (T) substituted
by uracil (U) and also deoxyribose by ribose [81].

(A)

(B)

Figure 3.1. Structure of DNA. (A) DNA and its building blocks. (B) Complementary
base-pairing in the DNA double-helix [81].
In a living cell, during the process of transcription, the genetic information
contained within its double-stranded DNA is transferred onto the messenger RNA
(mRNA). While in translation, the mRNA is decoded to produce a specific polypeptide at
the ribosome. The rules for the synthesis of a polypeptide chain are specified by the
genetic code, which defines a mapping between tri-nucleotide sequences called ‘codons’
and amino acids. Each codon specifies a single amino acid [82], Most organisms use a
universal codon usage referred to as standard genetic code such as the one for
Escherichia coli (E.coli) K12 strain as shown in Appendix C.
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3.1.1.2. Codon bias
The frequencies with which different codons appear in E.coli genes are different
from those in human. The frequency of any codon reflects the amount of tRNA specific
to that codon. As such any tRNA that recognizes a rarely used codon is present in low
amounts. Therefore, human genes that contain rare codons in E.coli may be inefficiently
expressed. Hence, this problem can be solved either by exchanging codons in the target
gene for codons more frequently used in E.coli, or, alternately, by co-production of the
rare tRNAs [83].
3.1.1.3. Polymerase chain reaction
Polymerase chain reaction (PCR), developed by Kary Mullis in 1983, is a
molecular biology technique which allows a small amount of DNA molecule to be
amplified many times, in an exponential manner. A PCR requires several basic
components such as DNA template or cDNA, which contains the region of the DNA
fragment to be amplified; two primers that determine the beginning and end of the region
to be amplified; DNA polymerase such as Taq or Pfu, which copies the region to be
amplified; deoxynucleotide triphosphates (dNTPs), from which the DNA polymerase
builds the new DNA and a buffer which provides a suitable chemical environment for the
DNA polymerase [84].
A PCR process usually consists of a series of twenty to thirty-five cycles. Each of
these cycles consists of the following three steps. The first step is called denaturing,
where the double-stranded DNA (dsDNA) template is heated to 94-96° C to break the
hydrogen bonds connecting the two DNA strands. In the second step of annealing, the
temperature of the reaction mixture is lowered to around 55°C at which the primers are
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hybridized onto the template. The final step called extension, involves raising the
temperature o f the reaction mixture to 72°C at which the DNA polymerase starts at each
of the annealed primers and copies the DNA strands by extending the primers. A
schematic of the PCR process is as shown in Figure 3.2. At the end of first PCR cycle,
there would be two copies of the template DNA as shown. As such at the end of 30
cycles, 230 copies of the template DNA would be present.
• 3'
• 5’
| Denaturatjon

Annealing

— 5'
Extension

Annealing

3’i^ ^ h
Extension

5 '.
3 'a

Figure 3.2. Schematic o f the PCR process. All the three steps involved in the first cycle
of PCR are shown here. ‘P’ indicates DNA polymerase.

In this current project, PCR has been employed in multi-stage to synthesize the
C2 domain gene as described in Section 3.1.2.1.
3.1.1.4. DNA electrophoresis
It is an analytical technique used to separate DNA fragments based on their size.
This technique employs agarose, a polysaccharide polymer material extracted from
seaweed. Because agarose contains large number of hydroxyl groups, it readily forms
low-melting point gels with aqueous buffers and creates an immobile meshwork of
microscopic fibers. The DNA fragments to be separated are loaded onto different wells in
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an agarose gel and are made to migrate through it by the application of an electric field.
Due to the net negative charge of the phosphate backbone of a DNA chain, DNA
molecules are normally made to migrate from negative to positive potential. Smaller
DNA fragments migrate faster through the meshwork, whereas the larger ones migrate
slower. To visualize the DNA, ethidium bromide, a fluorescent dye that intercalates the
double stranded DNA during the migration is generally used. The sizes of unknown DNA
bands are determined by comparing them to a set of DNA markers [85].
3.1.2. Methods. Results and Discussion
This section consists of various subtopics covering the experimental methods
involved in the design and synthesis of the C2 domain gene including their results and
discussion.
3.I.2.I. Design of the C2 domain eene
As the first basic step, the amino acid sequence of human tensin under accession
number NP 072174 was acquired from the protein database of National Center for
Biotechnology Information (NCBI). Boundaries for each of the domains of tensin have
been identified by their sequence homology alignment with the respective domains in
other known proteins. Once the domain boundaries were identified for the C2 domain,
the genes that would encode for its amino acids were built. Also, this was done by
picking up only the high frequency codons from the codon usage table of Escherichia
coli K12 strain as shown in Appendix C.
After the gene for the C2 domain has been built, restriction enzyme sites viz Nde I
and Xho I were incorporated at its 5’ and 3’ ends respectively. A stop codon was also
added in the gene design just preceding the Xho I site to terminate the amino acid chain
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during translation. At the 5’-end of the C2 domain gene, a Bel I site was incorporated a
few bases following the Nde I site so that it could be linked to the C-terminal region of
the PTP gene. Care was also taken to include sufficient bases on either side of the
restriction enzyme sites for efficient cleavage. The C2 domain gene designed after
incorporating the above features is shown in Figure 3.3.

Nde I site
I
AGGGAATTC CATATG TCGGGCT C CATTAAAATGAATAATAAAC CACTGTTT
H M
R E F
TCCCTTAAGj g t a t a c a g c c c g a g g t a a t t t t a c t t a t t a t t t g g t g a c a a a
Afl Il^site
CTGCATCACGTGATCAfTGCATGGTATTCCGAATTTTGAAAGCAAAGGTGGC
GACGTAGTGCtACTAGTjACGTACCATAAGGCTTAAAACTTTCGTTTCCACCG
TGTCGTCCTTTTTTACGTATCTATCAGGCGATGCAGCCTGTATACACCAGC
ACAGCAGGAAAAAATGCATAGATAGTCCGCTACGTCGGACATATGTGGTCG
GGCATTTATAACATTCCGGGCGATTCCCAGACGAGCGTATGCATAACCATC

G

I * a I p.Gi-n

Uvmit&rf*#*.--'C--*#.%<&

CCGTAAATATTGTAAGGCCCGCTAAGGGTCTGCTCGCATACGTATTGGTAG
GAACCGGGCCTCCTTCTGAAAGGGGACATTCTGCTTAAATGCTACCATAAA
E
P G L L L K
CTTGGCCCGGAGGAAGACTTTCCCCTGTAAGACGAATTTACGATGGTATTT
AAATTCCGCAGCCCGGCTCGCGACGTCATCTTCCGCGTGCAATTTCATACG
K F R S P A R D V X F R V Q F H T
TTTAAGGCGTCGGGCCGAGCGCTGCAGTAGAAGGCGCACGTTAAAGTATGC
TGCGCGATTCATGATCTGGGCGTAGTGTTCGGTAAGGAAGACCTAGATGAT
c a : H D
G V V F
G K E D
ACGCGCTAAGTACTAGACCCGCATCACAAGCCATTCCTTCTGGATCTACTA
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GCCTTCAAAGATGATCGCTTTCCAGAGTATGGGAAAGTAGAATTCGTCTTT
A F
D D R F
CGGAAGTTTCTACTAGCGAAAGGTCTCATACCCTTTCATCTTAAGCAGAAA
AGTTACGGC C CTGAGAAAAT C CAAGGCATGGAACATCTGGAAAACGGCCCG
TCAATGCCGC^^TCTTTTAGCTTCCGTACCTTGTAGACCTTTTGCCGGGC
TCTGTAAGCGTGGACTATAATACTAGTGATCCGCTTATTCGTTGGGATTCC
AGACATTCGCACCTGATATTATGATCACTAGGCGAATAAGCAACCCTAAGG
TACGATAACTTCTCCGGCCACCGTGATGACGGCATGGAAGAAGTAGTTGGT
ATGCTATTGAAGAGGCCGGTGGCACTACTGCCGTACCTTCTTCATCAACCA
Xho I site

Figure 3.3. Design of the C2 domain gene. The highlighted text in bold indicates the
amino acid sequence that would be encoded by the C2 domain gene. The sequences of
the corresponding coding and non-coding strands are indicated just above and below it
respectively. **’ indicates a stop codon.

3.I.2.2. Synthesis of the C2 domain
gene by PCR
Ten oligonucleotides, five each from the coding and the non-coding strands (sets
o f bases that are underlined in Figure 3.3) were chosen from the gene design so that these
oligonucleotides would serve as templates for the synthesis of full length double-stranded
C2 domain gene. The schematic of the PCR strategy used is as shown in Figure 3.4.
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PCR-1
USl ( 7 4 )

P C R -II

U S 2 (79)

L S I (74 )

US3 ( 7 6 )

LS2 ( t l i

P C R -III

US4 ( 7 6 )

LS3 ( 7 5 )

U S 5 (78)

LS4 <$0;>

LS5 (75!)

PC R -IV
D S 2 (246)
DS3(132)

PCR-V

DS1(235)
DS4 ( 3 5 8 )

C 2 (573)

Figure 3.4. Schematic of the PCR strategy to synthesize the C2 domain gene.

The five oligonucleotides from the coding strand are indicated U Sl, US2, US3,
US4 and US5, while the five from non-coding strand are LSI, LS2, LS3, LS4 and LS5.
The sequences of each of these oligonucleotides from 5’ to 3’ ends are shown below with
their lengths indicated in parentheses.
USl - AGGGAATTCCATATGTCGGGCTCCATTAAAATGAATAATAAACCACTGT
TTCTGCATCACGTGATCATGCATGG (74)
US2 - GTCCTTTTTT ACGT ATCT AT CAGGCGAT GC AGCCT GTAT AC ACC AGCGG
CATTTATAACATTCCGGGCGATTCCCAGAC (79)
US3- CCTTCT GAAAGGGGAC ATT CT GCTTAAAT GCTACC AT AAA AAATTCCGC
AGCCCGGCTCGCGACGTCATCTTCCGC (76)
US4- CGTAGTGTTCGGTAAGGAAGACCTAGATGATGCCTTCAAAGATGATCGC
TTTCC AGAGT AT GGGAAAGT AGA ATT C (76)
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US5- CATCTGGAAAACGGCCCGTCTGTAAGCGTGGACTATAATACTAGTGATC
CGCTT ATT CGTT GGGATTCCT AC GATA AC (78)
LSI - GATAGATACGTAAAAAAGGACGAC AGCC ACCTTTGCTTTC AAAATTCGG
AAT ACC AT GCAT GAT CACGT GAT GC (74)
LS2- GAATGTCCCCTTTCAGAAGGAGGCCCGGTTCGATGGTTATGCATACGCT
CGTCTGGGAATCGCCCGGAATG (71)
LS3- CTTCCTTACCGAACACTACGCCCAGATCATGAATCGCGCACGTATGAAA
TT GC ACGCGGAAGAT GACGT CGCGAG (75)
LS4- GACGGGCCGTTTTCCAGATGTTCCATGCCTTGGATTTTCTCAGGGCCGTA
ACTAAAGACGAATTCTACTTTCCCATACTC (80)
LS5-CCGCTCGAGTTAACCAACTACTTCTTCCATGCCGTCATCACGGTGGCCGG
AGAAGTT ATCGT AGGAAT CCC AACG (75)
The strategy to synthesize the full length C2 gene involved several steps. Initially
the ten oligonucleotides above were grouped into 3 sets of four, four and two
respectively. The next step involved performing an overlap-extension PCR using the four
oligonucleotides U Sl, LSI, US2 and LS2 to yield the double-stranded DNA fragment
DS1 as shown in Figure 3.4. Similarly, performing an overlap-extension PCR of oligos
US3, LS3, US4 and LS4 would yield the double-stranded DNA fragment DS2, while the
overlap-extension PCR o f oligos US5 and LS5 would yield the fragment DS3. To
amplify each of the fragments DS1, DS2 and DS3, two different end primers were
designed, the sequences o f which are as shown below:
Pl-AGGGAATTCCATATGTCGG (19)
P2-GAATGTCCCCTTTCAGAA (18)
P3-CCTTCTGAAAGGGGACATTCTGCT (24)
P4-GACGGGCCGTTTTCCAGATGTTCCA (25)
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P5-CATCTGGAAAACGGCCC (17)
P6-CCGCTCGAGTTAACCAACTACTTCT (25)
The lengths of each of the starting oligos were kept in the range of 70-80 bases.
The overlapping regions of the successive oligos were also kept to be around 20 bases in
length. These regions would start and end with GC pairs for better annealing.
In the next step, overlap-extension PCR on DS2 and DS3 would yield another
double-stranded DNA fragment DS4. In the final step, overlap-extension PCR on the
fragments DS1 and DS4 would yield the entire C2 domain gene.
All the oligonucleotides and primers were received from a commercial source in
lyophilized form. The optical density of the oligonucleotides was 15 at 260 nm, while
that o f the primers was 10 at 260 nm. Stock solutions were prepared by initially adding
500pl of DI water to each o f the oligonucleotide vials. Amounts of 90 pi, 100 pi, 76 pi,
75 pi, 105 pi and 76 pi o f DI water were added to the primer vials PI, P2, P3, P4, P5 and
P6 respectively. The resulting oligonucleotide calculations and their concentrations after
initial dilution are as shown in Table 3.1. The formulae used are shown in Appendix D.

Table 3.1. Oligonucleotide calculations and their concentrations after initial dilution.

Oligo/Primer
US1
LSI
US2
LS2
US3
LS3
US4
LS4
US5
LS5

G

C

T

E260
(IVf'cnT1)

Mol.wt
(Da)

pmol

Pg

23 15
26 15
18 16
14 22
19 15
21 18
23 21
17 16
20 18
18 17

15
16
22
18
24
22
12
22
18
23

21
17
23
17
18
14
20
25
22
17

737267.1
753625.3
740328.7
674628.9
717322.2
731704.6
772591.2
742304.5
754809.0
710068.7

22805.88
22818.06
24201.93
21942.37
23243.24
23062.09
24497.14
24025.84
24025.84
22995.06

20345.4
19903.79
20261.27
22234.44
20911.10
20500.70
19415.18
20207.34
19872.57
21124.71

463.99
454.16
490.36
487.87
486.00
472.77
458.38
495.02
477.45
485.76

A
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Stock
Cone
(pg/pl)
0.92798
0.90832
0.98072
0.97574
0.97200
0.94554
0.91676
0.99000
0.95000
0.97152
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PI
P2
P3
P4
P5
P6

5
5
7
7
2
7

6
3
6
7
4
3

3
5
6
7
6
9

5
5
7
7
2
7

190664.7
172330.7
226015.5
229237.3
165700.2
227991.3

5867.85
5468.63
7343.86
7649.06
5164.39
7536.9

52448.09
58027.96
44244.70
43622.91
60349.95
43861.32

307.75
317.33
324.92
333.6
311.67
330.57

3.41900
3.17330
4.27000
4.44000
2.96000
4.34960

To 10 pi of each of US1, LSI, US2, LS2, US3, LS3, US4, LS4, US5 and LS5,
82.8 ill, 80.8 pi, 88 pi, 87.6 pi, 87.2 pi, 84.5 jul, 81.7 pi, 89 pi, 85 pi and 87.15 pi of DI
water was added respectively to get a final oligo concentration of 100 ng/pl. Also to 3 pi
of each of P I, P2, P3, P4, P5 and P6, 99.5 pi, 92.2 pi, 125.1 pi, 130.2 pi, 85.8 pi and
127.5 pi o f DI water was added respectively to get a final primer concentration of 100
ng/pl.
Initially, to synthesize the double stranded piece DS1, the following components
were taken into a PCR tube:
Oligo-USl---------------------1.0 pi (100 ng/pl)
Oligo-LSl--------------------- 1.0 pi (100 ng/pl)
01igo-US2---------------------1.0 pi (100 ng/pl)
01igo-LS2--------------------- 1.0 pi (100 ng/pl)
Pfu polymerase--------------- 1.0 pi (2.5 U/pl)
lOx Pfu buffer-----------------5.0 pi
dNTP mix (25mM each)

0.8 pi

DI water------------------------ 39.2 pi
The components were mixed well using a pipette, after which the PCR tube was
placed in one o f the sample wells of the thermal cycler. Then its components were
subjected to the following thermal cycles:
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94°C-------------------- 1 min

25°C------------------- 10 min
65°C

1 cycle

15min

94°C------------------- 1 min
55°C------------------- 1 min

1 cycle

72°C------------------- 1 min
Thereafter, 1.25

jj.1

of each of the primers PI and P2 at 100 ng/pl concentration

were added to the above PCR tube, mixed well and was further subjected to the following
thermal cycles:
94 C

1min

94°C

1min

55°C

1min

72°C

1min.

72°C

5min

j.—f cycle

^ 3 5 cycles

1 cycle
10°C-------------------- Hold
After all the cycles were completed, the resulting sample was taken out, mixed
with 10 pi o f 6x loading dye and then loaded onto two lanes of a 1.5% (w/v) agarose gel
that was prepared as per the protocol B.l in Appendix B. The gel was run at 60 V, 400
mA for 1 hour. After that, the gel was visualized on a UV transilluminator and was
photographed. The gel image thus obtained is as shown in Figure 3.5. The gel clearly
showed DNA bands at around 235 bp size, indicating the synthesis of the double-stranded
DS1.
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Figure 3.5. Agarose gel image showing the synthesis of the double-stranded DNA
fragment, DS1.

Later the bands from the agarose gel were excised and the DNA within was
extracted by gel extraction procedure as per the protocol B.l described in Appendix B.
Next to synthesize the double-stranded DS2, the following components were
taken into two PCR tubes separately.
01igo-US3----------------------1.0 pi (100 ng/pl)
01igo-LS3

1.0 pi (100 ng/pl)

01igo-US4----------------------1.0 pi (100 ng/pl)
01igo-LS4

1.0 pi (100 ng/pl)

Pfu polymerase---------------- 1.0 pi (2.5 U/pl)
lOx Pfu buffer----------------- 5.0 pi
dNTP mix (25mM each)

0.8 pi

DI water-------------------------39.2 pi
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After being mixed well, the components in the PCR tubes were subjected to the
following thermal cycles:
94°C------------------- 1 min
25°C------------------- 10 min

1 cycle

65°C------------------- 15 min
94°C------------------- 1 m i n '
55°C------------------- 1 min

^>- 1 cycle

72°C------------------- 1 min ^
Thereafter, 1.25 pi o f each of the primers P3 and P4 at 100 ng/pl concentration
were added to the above PCR tubes and were further subjected to the following thermal
cycles:
a 0^~i

-»

94 C---------------------1 min

.

-1 cycle

94 C---------------------1 min
55 C---------------------1 min

>~35 cycles

72 C---------------------1 min
72 C-------------------- 5 min
1 cycle

After all the cycles were completed, the resulting tubes were taken out and the
components loaded onto a 1.5% (w/v) agarose gel. The gel after it was run was visualized
on a UV transilluminator and is as shown in Figure 3.6. The gel clearly showed DNA
bands at around 246 bp size, indicating the synthesis of the double-stranded DS2. As
before, the bands were excised and the DNA within was extracted and stored.
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Figure 3.6. Agarose gel picture showing the synthesis of the double-stranded DNA
fragment, DS2.

Next, to synthesize the double stranded fragment DS3, the following components
were taken into two PCR tubes separately:
01igo-US5

1.0 til (100 ng/pl)

01igo-LS5

1.0 pi (100 ng/pl)

Pfu polymerase---------------- 1.0 pi (2.5 U/pl)
lOx Pfu buffer
dNTP mix (25mM each)

5.0 pi
0.8 pi

DI water-------------------------41.2 pi
After being mixed well, the components in the PCR tubes were subjected to the
following thermal cycles:
94°C------------------- 1 min """
25°C------------------- 10 min

^>-1 cycle

65°C------------------- 15 min
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94°C---------------------1 min

55°C--------------------1 min

J>-1 cycle

72°C--------------------1 min
Thereafter, 1.25 pi of each of the primers P5 and P6 at 100 ng/pl concentration
were added to the above PCR tubes and were further subjected to the following thermal
cycles:
94°C-------------------- 1 min ^ } ~ 1 cycle
94°C-------------------- 1 min
55°C-------------------- 1 min

,>~35 cycles

72°C-------------------- 1 min
72°C-------------------- 5 min
1 cycle
10°C-------------------- Hold
After all the cycles were completed, the resulting tubes were taken out and the
components loaded onto a 1.5% (w/v) agarose gel. The gel after it was run as visualized
on a UV transilluminator is shown in Figure 3.7. The gel clearly showed DNA bands at
around 132 bp size, indicating the synthesis of the double-stranded DS3.
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Figure 3.7. Agarose gel image showing the synthesis of the double-stranded DNA
fragment, DS3.
Next, each o f the gel extracted double-stranded fragments DS1, DS2 and DS3,
were amplified by their corresponding primers in three separate PCR tubes as follows. In
addition to 1 pi (100 ng/pl) of the each of the template and 1.25 pi (100 ng/pl) of the
corresponding primers, the following components were also taken into each of those
tubes.
Pfu polymerase--------------- 1.0 pi (2.5 U/pl)
lOx Pfu buffer-----------------5.0 pi
dNTP mix (25mM each)

0.8 pi

DI water------------------------ 41.2 pi
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After being mixed well, the components were subjected to the following thermal
cycles:
94°C---------------------1 m in'

1 cycle

94°C---------------------1 min
55°C---------------------1 min

>~35 cycles

72°C---------------------1 min.
72°C-------------------- 5 min
1 cycle
10°C-------------------- Hold
Thereafter the contents of each of those tubes were loaded onto a 1.5% (w/v)
agarose gel. The gel after it was run was visualized and photographed. The gel image as
in Figure 3.8 clearly shows that all the three double-stranded pieces were successfully
amplified.

Kaprcse/TAE
Figure 3.8. Agarose gel image showing the amplification of the double-stranded DNA
fragments DS1, DS2 and DS3.
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Next to synthesize the double-stranded fragment DS4 from DS2 and DS3, the
following reaction components were taken into two separate PCR tubes:
DS2--------------------- 1.0 pi (100 ng/pl)
DS3--------------------- 1.0 pi (100 ng/pl)
DI water--------------- 39.6 pi
The above tubeswere subjected to denaturation at 94 °C for 10minutes. Then the
tubes were taken out

of the thermal cycler and vortexed.Thereafter

the following

components were added:
Pfu polymerase----------------- 0.5 pi (2.5 U/pl)
lOx Pfu buffer

5.0 pi

dNTP mix (25mM each)

0.4 pi

Then the components in the PCR tubes were subjected to the following thermal
cycles:
94°C-------------------1 min
25°C-------------------10 min

j>—l cycle

65°C------------------ 15 min
94°C-------------------1 min ~
55°C------------------ 1 min

> -1 cycle

72°C------------------ 1 min ______
After that, 1.25 pi o f each of the primers P3 and P6 at 100 ng/pl concentration
were added to the above PCR tubes and were further subjected to the following thermal
cycles:
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55°C--------------------1 min

✓>- 35 cycles

72°C--------------------1 min
72°C--------------------5 min
1 cycle
10°C--------------------Hold
After all the cycles were completed, the components were loaded onto a 1.5%
(w/v) agarose gel. The gel thus obtained showed DNA bands at around 359 bp size,
indicating the synthesis o f the double-stranded DS4 as in Figure 3.9.

2%a#w»e/TAE
Figure 3,9. Agarose gel image showing the synthesis of the double-stranded DNA
fragment, DS4.

The bands on the gel thus obtained were excised and the DNA within, was
extracted as before and stored. After verifying the amplification of DS4 with its end
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primers, synthesis of DS5 was attempted using DS1 and DS4. The following components
were taken into two separate PCR tubes:
DS1---------------------1.0 pi (100 ng/pl)
DS4---------------------1.0 pi (100 ng/pl)
Pfu polymerase---------------- 0.5 pi (2.5 U/pl)
lOx Pfu buffer

5.0 pi

dNTP mix (25mM each)-----0.4 pi
DI water

41.2 pi

The components in the two tubes were then subjected to the following thermal
cycles:
94°C------------------ 10 min"
35°C------------------ 3 min
5 cycles
60°C

3 min

72 °C--------------------1 min
Thereafter, 1.25 pi o f each of the primers PI and P6 at 100 ng/pl concentration
were added to the above PCR tubes along with 0.5 pi of Pfu polymerase and 0.3 pi of
dNTP mix and were further subjected to the following thermal cycles:
94°C

1min

\— l cycle

94°C--------------------- 1min
55 C---------------------1 min

35 cycles

72 C---------------------1 min
72 C---------------------10 min

1 cycle
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Thereafter, the contents of both the tubes were loaded onto a 1.5% (w/v) agarose
gel and were run. The gel thus obtained is as shown in Figure 3.10. The gel clearly
showed bands at 573 bp size.

Figure 3.10. Agarose gel picture showing the synthesis of the double-stranded, DS5.

The bands from the gel were cut and the DNA extracted and stored. Thereafter,
the double-stranded DS5 was attempted to be amplified using the end primers, PI and P6.
In spite of many attempts, the gene could not be amplified. As such an alternative method
to synthesize the C2 domain gene was sought as described in Section 3.1.2.3.
3.1.2.3. Alternate method for the C2 domain
gene synthesis
A 552 bp gene corresponding to the C2 domain and consisting of only the highest
frequency codons was ordered from a commercial source to be synthesized and cloned
into a pDrive cloning vector. The 552 bp gene ordered is as shown in Figure 3.11.
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ATGACGGGCTCCATTAAAATGAACAACAAACCGCTGTTTCTGCATCATGTG
M T 6 S
I
K M N N K P
L F L » H V
TACTGCCCGAGGTAATTTTACTTGTTGTTTGGCGACAAAGACGTAGTACAC
ATCATGCATGGCATTCCGAACTTTGAAAGCAAAGGCGGCTGCCGCCCGTTT
i
m
h
g
i
p
s
f
t - M .
S i t ,* . .. , jp
TAGTCCGTACCGTAAGGCTTGAAACTTTCGTTTCCGCCGACGGCGGGCAAA
CTGCGCATTTATCAGGCGATGCAGCCGGTGTATACCAGCGGCATTTATAAC
GACGCGTAAATAGT C CGCTACGT CGGC CACATATGGT CGCCGT AAATATTG
ATTCCGGGCGATAGCCAGACCAGCGTGTGCATTACCATTGAACCGGGCCTG
TAAGGCCCGCTATCGGTCTGGTCGCACACGTAATGGTAACTTGGCCCGGAC
CTGCTGAAAGGCGATATTCTGCTGAAATGCTATCATAAAAAATTTCGCAGC
GACGACTTTCCGCTATAAGACGACTTTACGATAGTATTTTTTAAAGCGTCG
CCGGCGCGCGATGTGATTTTTCGCGTGCAGTTTCATACCTGCGCGATTCAT
GGCCGCGCGCTACACTAAAAAGCGCACGTCAAAGTATGGACGCGCTAAGTA
GATCTGGGCGTGGTGTTTGGCAAAGAAGATCTGGATGATGCGTTTAAAGAT
CTAGACCCGCACCACAAACCGTTTCTTCTAGACCTACTACGCAAATTTCTA
GATCGCTTTCCGGAATATGGCAAAGTGGAATTTGTGTTTAGCTATGGCCCG
d
r
f
p
e
t
a
CTAGCGAAAGGCCTTATACCGTTTCACCTTAAACACAAATCGATACCGGGC
GAAAAAATTCAGGGCATGGAACATCTGGAAAACGGCCCGAGCGTGAGCGTG
E K I Q G M E H L E N
G; P S V S V
CTTTTTTAAGTCCCGTACCTTGTAGACCTTTTGCCGGGCTCGCACTCGCAC
GATTATAACACCAGCGATCCGCTGATTCGCTGGGATAGCTATGATAACTTT
D Y N T S D P L I R W D S Y D N F
CTAATATTGTGGTCGCTAGGCGACTAAGCGACCCTATCGATACTATTGAAA
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AGCGGCCATCGCGATGATGGCATGGAAGAAGTGGTGGGCTAA
S G H R D D G M E E V V G *
TCGCCGGTAGCGCTACTACCGTACCTTCTTCACCACCCGATT
Figure 3.11. The 552 bp gene fragment used in the alternate method for the C2 domain
gene synthesis. **’ indicates a stop codon.

Two end primers were also designed for the above gene such that a PCR
performed on the pDrive cloning vector using them would yield the 573 bp C2 gene,
which can later be cloned into a pET14b vector. The strategy to synthesize the C2 gene
by PCR using the pDrive cloning vector as the template and then cloning it into the
pET14b vector is illustrated in Figure 3.12.

forward primor
Multiple cloning sites
with HiseTtg sequence
(Ndel, Xhol Ac BaxnHI)

reverse primer

| PCR amplification
N’del

Xhol

T~-

Amp*

1

digestion

Amp*

Figure 3.12. The PCR and cloning strategy used for the C2 gene to be expressed in
E.coli.

The sequences of the forward primer, PF and the reverse primer, PR from 5’ to 3’
are given by AGGGAATTCCATATGACGGGCTCCATTAAAATG (33 bases) and
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CCGCTCGAGTTAGCCCACCACTTCTTCCA (29 bases) respectively. The two primers
were supplied in lyophilized form with an O.D of 5 at 260 nm. The oligonucleotide
calculations for the primers ‘PF’ and ‘PR’ are shown in Table 3.2.

Table 3.2. Primer calculations and their concentrations.

Primer

A

G

C

T

Mol.Wt
(Da)

E at 260nm
(M'1cm'1)

pmol

Pg

PF

11

8

6

8

10185.67

337488

14815.34

150.904

PR

5

4

13

7

8709.63

250810.9

19935.33

173.629

About 251.5 pi o f DI water was added to the vial of forward primer, PF to get a
stock concentration of 600 ng/pl. Similarly, 289.4 pi of DI water was added to the vial of
reverse primer, PR to get a stock concentration of 600 ng/pl.
Next, a hot start PCR was performed by assembling the following components
into a PCR tube:
C2 containing pDrive cloning vector-------- 1.00 pi (100 ng/pl)
Forward primer, PF------------------------------1.25 pi (600 ng/pl)
Reverse primer, PR------------------------------1.25 pi (600 ng/pl)
lOx Pfu polymerase buffer

5.00 pi

dNTP mix

2.00 pi (5 mM each)

DI water----------------------------------------- 38.80 pi
The above components were subjected to 94°C for 3 minutes in the thermal
cycler. After 3 minutes, 0.7 pi of Pfu polymerase was added to it and was further
subjected to the following thermal cycles:
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94°C

5 min

94°C

1 min

55°C

1 min

72°C

•2 min

72°C

10 min'

10°C

Hold

1 cycle

35 cycles

1 cycle

After the reaction was complete, the components were loaded onto a 0.7% (w/v)
agarose gel. The gel thus obtained is as shown in Figure 3.13. The bands obtained at 573
bp from the gel were cut and the DNA within extracted and stored.

Figure 3.13. Agarose gel image showing the synthesis of C2 gene by PCR from pDrive
cloning vector. Lane 2 shows the DNA marker, while all other lanes show the C2 domain
gene PCR product.

Thereafter, the gel extracted C2 gene was successfully amplified by PCR using
the end primers, PF and PR.
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3.2. Cloning of the C2 Domain Gene
3.2.1. Introduction
This section consists of various subtopics covering the theory and background
relating to the procedures involved in the cloning of the C2 domain gene.
3.2.1.1. Recombinant DNA technology
Recombinant DNA refers to the insertion of DNA from one type of organism to
another and allows one to construct any protein, simply by changing the genetic plans
that are used to build it. For this purpose, naturally occurring enzymes, called restriction
enzymes isolated from bacteria are used. These enzymes cut DNA at specific palindromic
sequences and create sticky or blunt ends [84]. Examples of various restriction enzymes
creating sticky and blunt ends in DNA are shown in Figure 3.14.

Alul

5 ’ . . .fl G^C
GTC T. . . 3 ’
3 ’ . . .T CaG
C^G H. . . 5 ’

ilaelll

5 ’ . . . G G^fc C. . . 3 ’
3 ’ . .. C C^G G. . . 5 ’

BamHI

5 ’ . . ■G^G.fl...I...?..c - .. 3 ’
3 ’ . . . C Q* T fl G^G. . . 5 ’

Hindlll

5 ’ . . .fltn..9...P..T T . . . 3 ’
3 ’ . . .T' T 'C G' fl^n. .. 5 ’

EcoRJ

5 ’ . . . G^fl fl T T c . . . 3 ’
3 ’ . . . C T T ’fl ‘ fl^G. . . 5 ’

Figure 3.14. Restriction enzymes producing sticky and blunt ends. Alul and Haelll
produce blunt ends, while BamHI, Hindlll and EcoRI produce sticky ends.

The sticky ends readily associate with other sticky ends of complementary
sequence such as that from a bacterial DNA and are stuck together using another enzyme
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called DNA ligase. Once the ends are ligated, the resulting recombinant plasmid is used
to transform bacterial cells and is multiplied within it as the bacterium divides. This
process is known as DNA cloning. Any protein of interest is generally expressed in
engineered cells, using expression vectors. These vectors are plasmids that contain the
gene specifying the protein along with a highly active promoter sequence. The promoter
then aids in the production of messenger RNA in large quantities based on the plasmid
DNA in the vector. Finally at the ribosomes, the cell synthesizes protein of interest in
large quantities based on this messenger RNA.
3.2.I.2. pET14b vector
pET14b was the vector o f choice for the cloning and expression of the C2 domain
gene. It has an N-terminal hexa-histidine tag followed by a thrombin site and three
cloning sites as can be seen from its cloning/expression region in Figure 3.15.

/•W
lH
H
M
I

/.JO****
'^A
mk’txcrt
♦Jcslvr-

p6T*14b

<«?']»;

T 7 p ro m o te r
AGATCTCGATCCCGCGAAATTAATACBACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAACGASA
TArACCATGGGCAGCAGCCA7CATCATCATCATCACAGCAGCGGCCTGGTGCCGCGGGGCAGCCATATGCTC8AGGArCCGCCTGCTAACAAAGCCCGA
H « t C I y S * r S * r H i k H I I H i * H 1«M t s H l » S * r S » r G I y i » u V o I P r o A r q C ) y S o r H I a h « t l l u A * p P r o A I o A l o A g n ly « A l o A r g
B po 1 1 0 2 1
th r o m b in
T7 f rm tn to r

Bpuutt I

A
A
G
GAAGCTCAerTGGCrGCTGCCACCGCTGAGCAATAACtAGCATAACCCCTTGGGCCC’TCrAAACOOOrCTTCASGCQTrrTrTe
( y « C f u A Ia G Iu l « u A Ia A Io A I a t

7

30337-3

Tte
rm
in
a
to
rp
rim
e
rI
H

Figure 3.15. Vector map of pET14b with its cloning/expression region [87]
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Ndel and Xhol are the two sites chosen to clone the C2 domain gene. More about
the features of the pET system are discussed in Section 4.1.1.3.
3.2.I.3. DNA sequencing
It is usually done by employing the dideoxy method in which DNA is synthesized
by PCR in the presence of chain-terminating dideoxyribonucleoside triphosphates. To
determine the complete sequence of a DNA fragment, the double-stranded DNA is first
separated into its single strands, and one of the strands is used as the template for
sequencing, which consists of four separate DNA synthesis reactions. In each of these
reactions, along with the template, there exists DNA polymerase, a short primer, the four
deoxyribonucleoside triphosphates (dATP, dGTP, dCTP, dTTP) and one of the four
different dideoxyribonucleoside triphosphates (ddATP, ddGTP, ddCTP, ddTTP). The
dideoxyribonucleoside triphosphates lack the 3’ hydroxyl group in comparison to the
normal deoxyribonucleoside triphosphates as shown in Figure 3.16. Hence during the
above reactions, when the growing DNA chain encounters the dideoxyribonucleotide
present, the addition o f the next nucleotide is blocked and the DNA chain is terminated.
Each o f the above reactions produces a set of DNA copies that terminate at different
points in the sequence. The products of these four reactions are then separated by
electrophoresis in four parallel lanes of a polyacrylamide gel. The newly synthesized
fragments are detected by a radioactive or a fluorescent label that had been incorporated
into the primer or into one of the deoxyribonucleoside triphosphates. In each lane, the
bands represent fragments that have terminated at a given nucleotide but at different
positions in the DNA. By reading off the bands in order, starting at the bottom of the gel
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and working across all lanes, the DNA sequence of the newly synthesized strand can be
determined [81].

deoxyribonucleoside triphosphate

0 0 ( p^

o —ot.

y

y

.,>

dideoxyribonucleoside triphosphate

<£X£X£H-o-ot.

fS—
r

o h

allows strand extension at 3' end

/

*

Prev9n*s strand »>^nsion at 3’ end

Figure 3.16. Chemical structures of deoxy- and dideoxyribonucleoside triphosphates
[81].

3.2.2. Methods, Results and Discussion
The subtopics within this section deal with the experimental methods used in the
cloning of the C2 domain gene including their results and discussion.
3.2.2.I. Cloning of the C2 domain gene
Initially, restriction enzyme digestion of the pET14b vector was performed by
arranging the following components in a PCR tube:
RE lOx buffer--------------------------- 4.00/d
Acetylated BSA------------------------- 0.40/d (10/ig//d)
pET 14b vector-------------------------- 1.00/d

(100 ng/jd)

Nde /restriction enzyme---------------1.00/zl (10U//d)
DI water-------------------------------- 32.10 /d
The PCR tube was then incubated at room temperature for 12 hours. After that 1.5
fil of Xho I (10 U/pl) was added to it and the restriction digestion was continued for
another 5 hours. Thereafter, the product was PCR purified.
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Next, a restriction enzyme digestion for the C2 domain gene product was setup in
a PCR tube with the following components:
RE lOx buffer------------------------- 4.00 pi
Acetylated BSA

0.40 /d (10 pg/pl)

C2 gene product------------------------ 1.00 /d (100 ng/jd)
Nde I restriction enzyme

1.00 jd (10 U/jd)

Xho / restriction enzyme------------- 1.00 /d (10 U//d)
DI water----------------------------------32.60/d
The PCR tube was then incubated at room temperature for 8 hours. Thereafter, the
product was PCR purified. After the above two restriction digestion procedures, a ligation
reaction was setup in a PCR tube with the following components:
RE digested pET 14b---------------- 0.5 pi
RE digested C2 gene----------------- 3.0 pi
lOx T4 DNA ligase buffer-----------1.50 pi
T4 DNA ligase------------------------ 0.75 pi (0.5 U)
DI water-------------------------------- 9.25 pi
The above reaction sample was kept at 15°C overnight. After the reaction, the
ligation mixture was stored at -20°C. LB agar plates containing ampicillin at 5 pg/ml
final concentration were prepared as per the protocol B.4 in Appendix B. Three micro
centrifuge tubes, each containing 50 pi of XL2 blue ultra-competent cells were
transformed with 1 pi of uncut pET14b (1 pg/pl), 5 pi of the above ligation mixture, 5 pi
of the restriction digested pET14b respectively as per the protocol B.6 in Appendix B.
After the transformation, the three samples were plated onto the LB agar plates and then
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incubated at 37°C overnight. Next morning, upon the inspection of plates, it was found
that the positive control plate (uncut pET14b) had a lot of colonies as expected. The
negative control plate (cut pET14b) had five colonies, while the plate with the ligation
mixture had just one colony. This single colony formed was picked up and used to
inoculate 100 ml of freshly prepared LB broth containing 5 /ig/ml of ampicillin. LB broth
was prepared as per the protocol B.5 in Appendix B. The culture was then kept shaking
at 37°C overnight. The next morning, minipreps kit was used to extract the plasmid from
the transformed cell culture as per the protocol B.7 in Appendix B. After the plasmid
extraction, 10 /d of it was taken and was run on a 0.7% agarose gel along side 10 /d of
pET14b (50 ng/pl). The gel obtained thereafter is as shown in Figure 3.17. From the
figure, pET14b vector having a size of 4671 bp can be seen in Lanel, while the
recombinant C2 plasmid having an expected size of 5244 bp (4671+573) can be seen in
Lane 3. The difference in the sizes of both the plasmids does indicate the presence of an
insert within the recombinant plasmid.
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Figure 3.17. Agarose gel image showing the restriction digestion of pET14b and C2
containing pET14b. Lane 1: Petl4b; Lane 2: DNA marker; Lane 3: C2 containing
pET14b.

Again to check the presence of insert within the picked-up colony, the following
restriction enzyme tests were done. Four different restriction enzyme reactions were setup
in tubes A, B, C and D with components as shown in Table 3.3.

Table 3.3. Restriction enzyme reaction components for the C2 domain gene cloning.
Tube-A

Tube-B

Tube-C

Tube-D

lOx Restriction
enzyme buffer

4.0 pi

4.0pl

4.0pl

4.0pl

Acetylated BSA

0.4 pi
(lOpg/pl)

0.4 pi
(10 pg/pl)

0.4 pi
(10 pg/pl)

0.4 pi
(10 pg/pl)

C2-pET14b

4.0 pi

4.0 pi

4.0 pi

4.0 pi

Xhol

-

1.5 pi
(10 U/pl)

1.5 pi
(10 U/pl)

Ndel

1.0 pi
(lOU/pl)

-

-

1.5 pi
(10 U/pl)
1.0 pi
(10 U/pl)

DI water

32.1 pi

32.1 pi

30.6pl

29.1 pi
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All the tubes were then incubated at 37°C for 4 hours and later run on a 0.7%
agarose gel. The gel thus obtained is as shown in Figure 3.18. Lanes 1 and 2 that were
loaded with samples from tubes A and B respectively, show a single band at 4671 bp,
which represents the linearized pET14b. Lane 4 loaded with the sample from tube C
shows a single band at 5244 bp, which represents the linearized recombinant C2 plasmid.
Lane 5 loaded with the sample from tube D show a band at 4671 bp as expected.
However, the band corresponding to the insert could not be visible at 573 bp on the gel.

Figure 3.18. Agarose gel image showing the single and double restriction digestion
analysis of the recombinant C2 plasmid. Lanes 1 and 2: linearized pET14b vector; Lane
3: DNA marker; Lane 4: linearized recombinant C2 plasmid with single digestion and
Lane 5: linearized recombinant C2 plasmid with double digestion.
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To confirm the presence of the C2 insert within the recombinant plasmid by PCR,
the following components were set up in a PCR tube, T1:
1.00 fi\

C2 containing pET14b

Forward primer, PF------------------------------0.62 /d (100 ng//d)
Reverse primer, PR------------------------------ 0.62 /d (100 ng//d)
lOx Pfu polymerase buffer

2.50 /xl

dNTP mix------------------------------------------1.00 /d (5 mM each)
DI water

18.76 /d

Another PCR tube, T2 was used to accommodate with the same volumes of the
above components, except for the concentrations of both the primers, which was 600
ng//d. Both the tubes are subjected to PCR with the following thermal cycles:
94°C

5 min

94°C

1 min

55°C

1 min

72°G

■2 min

1 cycle

30 cycles

72°C------------------------- 10 min
10°C------------------------- H o l d

I

J

— 1 cycle

After the reaction, both the PCR products were run on a 0.7% agarose gel, along
side the restriction enzyme cut samples from tubes A and B. The resulting gel picture is
as shown in Figure 3.19. Both Lanes 1 and 2 show the linearized pET14b at 4671 bp.
Lanes 4 and 5 that were loaded with PCR products from tubes T1 and T2 respectively
show the evidence of the C2 domain gene insert within the recombinant C2 plasmid.
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Figure 3.19. Agarose gel image confirming the presence of the C2 gene insert within the
recombinant C2 plasmid. Lanes 1 and 2: linearized pET14b vector; Lane 3: DNA marker;
Lane 4: PCR product from tube T1 and Lane 5: PCR product from tube T2.

3.2.2.2. DNA sequencing of the C2 gene
After making sure that the insert present within the recombinant plasmid was at
the expected size of 573 bp, the recombinant C2 plasmid (C2 containing pET14b) was
sent to Retrogen, Inc (San Diego, CA) for DNA sequencing. Dideoxynucleotide method
o f sequencing was used for the sequence analysis of the recombinant C2 plasmid. Both
forward and reverse sequencing reactions were done using the T7 promoter and T7
terminator primers respectively. The sequencing results thus obtained were analyzed by
Chromas software. The chromatogram of the forward sequencing reaction of the
recombinant C2 plasmid using T7 promoter primer is as shown in Figure 3.20.
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H ie : 0 2 JC S G -1-C 2 _ T 7H R C M S 01 a b l
R u n E n d e d : N o v 2 3 , 2 0 0 4 , 1 7 :11:13
S ig n a l Q 10» « A 1 2 2 2 T :9 S4 C . U 71
C o m n e i* :
S » m ri» 0 2 -K S Q 4 T 7P R O M ____________ L an e : 7 B a s e g n c c t 1 4 .2 2 ____________8 0 7 b a n g a 9 6 5 3 x t a _________________ P a w l o f 2

GATCCSClfGlATATTITGTTT1CXXT11611G0161T1T1CCAX6G6CIOCIOCC1XC1TC1TClTClTC*ClGCIOCCGCCTOOTOCCOCOCGOC1C

L
OAT1TOACaG
110CCTCCATT12llA
0 XTOllCllC
12A
0AlCCGCTG1T4T
0TCTCC1TCIS
6C
0ATGCC1TT1C
7C
0O1ACTTTO11B10ACClA16C1C
M
CO
C
IO
TOT«1TC1T1G
6CCTC<

0C
0OTTTCTOC2O
10C1TTT2TC16
2260CO1TOC162C3C
0OOTOT1T1C
240C10COOClT2T0T
01T11C1TT2C
0C
00OOCO1T12C70CC1C1CC162C
006TOT6C1TT210C
0C1
CGC2C

2G
10CIGHAGOC3O
201T1ITCTOC3T3G
0AAATGCTA
2T
4C
01TAAll 1A3T8T
0TCGCAOCC2C
M
37O0TGATTTTT3C0O
0CGTGCA«TTTC
t TOAACCOGGCCTGCT
OGCGCOCOH

410
430
440
400
400
ITACCrOCOCOlTTCiTO
lTCTOOOCO430
IOOTOTTTOO
CAlAOliOAIC
TOOATOATO
COTTfllAOA
TOlTCOCrTT470
CCOOlATATO430
OCAllOTOOl

1&
00TTT6TOTTT
801O
0 CT1T00CC8C
1066111liltTC1006CIT6011C
830
830 1TCTOO8llllC
40 OCCCCO81«C
04 OTOlOCC8T0O
0O1TT1T11C
8701CCIOCO1T8C
80CCCTO

410
440
1TTCOCTOOOAIAOCTATO1T1A
CTTT10COOC430
CAXCOCOATO010
ATOOCATO0111
HOTOOtO480
OOCTAiCTCO440
100ATCC00C470
IOCTAACAAA3CCC01

Figure 3.20. Chromatogram of the forward sequencing reaction of the recombinant C2
plasmid using T7 promoter primer.
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The text sequence exported from the corresponding chromas file is as follows.
GATCCTCN GAAT ATTTT GTTT ACTTT A AG A AGGAGAT AT ACC AT GGGC AGC A
GCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATAT
GACGGGCTCCATTAAAATGAACAACAAACCGCTGTTTCTGCATCATGTGATC
ATGCATGGCATTCCGAACTTTGAAAGCAAAGGCGGCTGCCGCCCGTTTCTGC
GCATTTATCAGGCGATGCAGCCGGTGTATACCAGCGGCATTTATAACATTCCG
GGCGATAGCCAGACCAGCGTGTGCATTACCATTGAACCGGGCCTGCTGCTGA
AAGGCGATATTCTGCTGAAATGCTATCATAAAAAATTTCGCAGCCCGGCGCG
CGATGTGATTTTTCGCGTGCAGTTTCATACCTGCGCGATTCATGATCTGGGCG
T GGTGTTT GGC AA AG AAGAT CT GGAT GAT GCGTTT AAAG AT GATCGCTTTCCG
GAATAT GGC AAAGT GGAATTT GT GTTT AGCT AT GGCCCGG AA A AAATT CAGG
GCATGG AAC AT CT GGAAAACGGCCCG AGCGT GAGCGT GG ATT AT AAC ACC AG
CGATCCGCTGATTCGCTGGGATAGCTATGATAACTTTAGCGGCCATCGCGATG
ATGGCATGGAA|AAGTGGTGGGCTAACTCGAGGATCCGGCTGCTAACAAANC
CCGAAAGGAANCTGANTTGGCTGCTGCCACCGCTGANCAATAACTANCATAA
CCCCTTGGGGCCTCTAAACNGGTCTTGAGGGGTTTTTTGCTNAANGANGAACT
ATNTCCN GATNTN CNNNN GANN
The text highlighted in yellow corresponds well to the actual sequence of the C2
gene at every base except at the base numbered 640 (highlighted in green). The
chromatogram of the reverse complement of the reverse sequencing reaction of the
recombinant C2 plasmid using the T7 terminator primer is as shown in Figure 3.21.
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Figure 3.21. Chromatogram of the reverse complement of the reverse sequencing
reaction of the recombinant C2 plasmid using T7 terminator primer.
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The text sequence exported from the corresponding chromas file is as follows.
NNCCCNAANNGNNNANCCCNATNTTNCCCCNTNGNNGANGTNGGCNATATA
GGNGCCAGCANCCGCACCTGTGGNGCCGGTGANNCCGGCCNCGATGCGTCC
GGCGTAGAGGATCGAGATCTCGATCCCCGCGAAATTAATACGACTCACTATA
GGGAG ACC AC AACGGTTTCCCTCT AGAAAT AATTTT GTTT AACTTT AAGAAGG
AGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGG
TGCCGCGCGGCAGCCATATGACGGGCTCCATTAAAATGAACAACAAACCGCT
gtttctgcatcatgtgatcatgcatggcattccgaactttgaaagcaaaggcg

GCTGCCGCCCGTTTCTGCGCATTTATCAGGCGATGCAGCCGGTGTATACCAGC
GGCATTTAT AAC ATTCCGGGCG AT AGCC AGACC AGCGT GTGC ATTACC ATT G
AACCGGGCCTGCTGCTGAAAGGCGATATTCTGCTGAAATGCTATCATAAAAA
ATTTCGCAGCCCGGCGCGCGATGTGATTTTTCGCGTGCAGTTTCATACCTGCG
CGATT CAT GAT CT GGGCGT GGT GTTT GGC A AAG AAG AT CT GGAT GAT GCGTTT
AAAG AT GAT CGCTTTCCGG AAT AT GGC AA AGT GG AATTT GT GTTTAGCTAT G
GCCCGGAAAAAATTCAGGGCATGGAACATCTGGAAAACGGCCCGAGCGTGA
GCGTGG ATTAT AAC ACC AGC GAT CCGCT GATTCGCT GGG AT AGCTAT GAT AA
ctttagcggccatcgcgatgatggcatggaaI aagtggtgggctaactcgag

GATCCGGCTGCT AAC AAGCCCG AAGAAGN AT
The text highlighted in yellow again corresponded well to the actual sequence of
the C2 gene at every base including the one at the base numbered 640 (highlighted in
green) from the forward sequencing chromas file. Thus, it was concluded that the gene
corresponding to the C2 domain of human tensin was successfully synthesized, cloned
and sequence verified.
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CHAPTER 4
EXPRESSION, DETECTION AND PURIFICATION
OF THE C2 DOMAIN
4.1. Expression and Detection of the C2 Domain
4.1.1. Introduction
This section contains subtopics covering the theory and background information
relating to the procedures involved in the expression and detection of the C2 domain of
human tensin.
4.1.1.1. Gene expression systems
The different systems used for the heterologous expression of proteins are E.coli,
yeast, insect cells, and mammalian cells. Expression of proteins in E.coli is easy, quick
and cheap with the availability of many commercial and non-commercial expression
vectors with different N and C terminal tags. It also contains several different strains
which are optimized for special applications. More about E.coli is discussed in Section
4.1.1.2. Yeast is a eukaryotic organism that can be grown to very high densities and also
provides most of the eukaryotic post translational modifications such as phosphorylation,
glycosylation, acetylation and acylation. Insect cells are a higher eukaryotic system than
yeast and can carry out more complex post-translational modifications than E.coli and
yeast. They also have the best machinery for the folding of mammalian proteins and
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hence produce highly soluble proteins of mammalian origin. The disadvantages of insect
cells are the higher costs and low expression levels [88].
4.1.1.2. Significance and features of
Escherichia coli (E.coli)
E.coli is the most frequently used prokaryotic expression system for the production of
heterologous proteins. The advantages of E.coli are its ease of growth using inexpensive
media, rapid growth in comparison to higher cells, well-characterized genetics and the
availability of increasingly large number of cloning vectors and mutant host strains [89-91],
Virtually any gene can be expressed to a significant level in E.coli. However, the major
disadvantages are the frequent accumulation of expressed gene product as insoluble
aggregates called ‘inclusion bodies’ and the lack of extensive post translational processing
machinery as in higher cells [89, 90]. A typical E.coli expression vector consists apart from
the gene o f interest, an origin of replication, a gene that confers antibiotic resistance, a
promoter and a transcription terminator. The origin of replication determines the number of
plasmid copies. Plasmid instability generally occurs with multi-copy plasmids, when certain
number of cells inherits no copies of the plasmid upon cell division. As such the use of
expression vectors encoding an antibiotic resistance gene coupled with the addition of
antibiotics in the growth medium prevents plasmid instability.

There are many strong

promoters in E.coli that give very high rates of transcription initiation. Among those, tac,
lacUV5, and Ipp-lac are all regulated by the binding of the lac repressor and are derepressed
by the addition of isopropyl-j8-thiogalactoside (IPTG) [90-91].
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4.1.1.3. Regulation of protein expression
in pET system
An ideal promoter should be tightly regulated and completely shut off in the absence
of an inducing agent. But with most promoters, this regulation is not possible and there is a
basal level of transcription even in the absence of an inducing agent. As such the
recombinant protein expressed in E.coli may interfere in the normal functioning of the cell
and therefore may be toxic to the bacteria. The degree of toxicity varies from protein to
protein. All the native E.coli promoters and those that are controlled by the lac repressor are
leaky because they always have a basal level of transcription [91, 92].
The pET system, developed by Studier [93] and colleagues, is a powerful protein
expression tool because the protein expression can be tightly controlled. In pET vectors,
genes are expressed from T7 promoters, which are transcribed only by the T7 RNA
polymerase. T7 RNA polymerase is a very specific and active enzyme that carries out mRNA
chain elongation at a rate five times higher than the E.coli RNA polymerase. The pET
vectors are transformed in a strain carrying a T7 RNA polymerase gene in the chromosome
under the control of a lac promoter which is inducible by IPTG. Since there will be small
amount of T7 RNA polymerase even in the uninduced state, the resulting low level of
transcription is harmful to the cells, if the target gene product is toxic. To avoid this problem,
the pET vector containing the target gene is expressed in host strains such as pLysS or pLysE
(See Figure 4.1 A). These strains contain a compatible chloramphenicol-resistant plasmid that
provides a small amount of T7 lysozyme, which in turn is a powerful inhibitor of the T7
RNA polymerase (See Figure 4.IB). The T7 lysozyme thus synthesized by the host cells is
sufficient to inhibit transcription by the basal levels of T7 RNA polymerase [91, 92], In this
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present project, the C2 cloned pET-14b was transformed into BL21 (DE3) pLysS strain for
the tight regulation of protein expression.
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Figure 4.1. Regulation o f protein expression in the pET system. (A) Synthesis o f T7 RNA
polymerase. (B) Inhibition o f T7 RNA polymerase by T7 lysozyme in pLysS and pLysE host
strains [92].

4.1.1.4. Protein electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is the
most widely used method for analyzing protein mixtures qualitatively. SDS (CH 3 -(CH 2 )ioCH 2 0 S0 3 "Na+) is an anionic detergent. The protein samples to be run on SDS-PAGE are first
boiled for 5 minutes in sample buffer containing /3-mercaptoethanol and SDS. The
mercaptoethanol reduces any disulphide bonds present within the sample holding together
the protein tertiary structure, while the SDS binds strongly to the proteins and denatures
them. Each protein in the sample is fully denatured by this treatment and opens up into a rod
shaped structure with a series of negatively charged SDS molecules along the polypeptide
chain. The original native charge on the molecules is therefore completely saturated by the
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negatively charged SDS molecules. Apart from SDS and /3-mercaptoethanol, the sample
buffer also contains bromophenol blue, an ionizable tracking dye, that allows the
electrophoretic run to be monitored, and glycerol, which gives the sample solution density to
be settled onto the bottom of the loading well [94], In the preparation of gels for SDS-PAGE,
acrylamide is mixed with bisacrylamide to form a cross-linked polymer network (as in Figure
4.2), when the polymerizing agent ammonium persulphate is added.

For the same,

ammonium persulphate produces free radicals faster in the presence of TEMED (N, N, N,
N ’-tertamethylenediamine) [95].
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Figure 4.2. Polymerization and cross-linking o f acrylamide [95],

During SDS-PAGE, when the current is applied the negatively charged protein-SDS
complexes move towards the anode and because they have the same charge per unit length,
they travel into the gel under the applied electric field with the same mobility. However, as
they pass through the gel, the proteins separate. The smaller proteins migrate more easily
within the gel, while the larger proteins are retarded by frictional resistance due to the sieving
effect of the gel. The size of the pores created in the gel is inversely related to the amount of
acrylamide. Gels with a lower percentage of acrylamide are typically used to resolve large
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proteins, while gels with higher percentage of acrylamide are used to resolve smaller proteins
[95], Typically, the resolving gels used are 15% polyacrylamide gels. All the electrophoresis
experiments used in the expression and purification of the C2 domain of human tensin were
made of 12% polyacrylamide.
4.1.1.5. Protein (Western) blotting
Protein blotting is a method in which a pattern of separated proteins from a gel are
transferred onto a sheet o f nitrocellulose paper. This transfer is done by passing a current at
right angles to the gel, which causes the separated proteins to electrophorese out of gel and
into the nitrocellulose sheet. The nitrocellulose with its transferred protein is called as a blot.
Once transferred onto the nitrocellulose, the blot is probed by using an antibody to detect a
specific protein. The blot is first incubated in a protein solution usually 10% (w/v) bovine
serum albumin (BSA) or 5% (w/v) non-fat dried milk, which will block all the remaining
hydrophobic binding sites on the nitrocellulose sheet. The blot is then incubated in the
diluted solution o f primary antibody (IgG) directed against the protein of interest. This IgG
molecule will bind to the blot if it detects its antigen, thus identifying the protein of interest.
To visualize this interaction, the blot is incubated further in a solution of a secondary
antibody. This secondary antibody is appropriately labeled so that its interaction with
primary antibody can be visualized on the blot. One of the most common detection methods
uses an enzyme-linked secondary antibody. In this method, following treatment with
enzyme-linked secondary antibody, the blot is incubated in enzyme-substrate solution. Then,
the enzyme coverts the substrate into an insoluble colored product precipitated onto the
nitrocellulose. The presence of colored band therefore indicates the position of the protein of
interest. By careful comparisons of the blot with a stained gel of the same sample, the protein
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o f interest can be identified. One o f the enzymes used in enzyme-linked antibodies is
horseradish peroxidase, which, with H 2 O2 as substrate, oxidizes 4-chloro-l-napthol into an
insoluble blue product [97].
Dot blot is very similar to the western blotting except that the proteins are applied
directly onto the nitrocellulose rather than transferred from a gel. Cell lysates containing the
over expressed protein can also be applied to the nitrocellulose membrane in dot blot
procedures. In the detection of histidine tagged C2 domain, Penta-His HRP conjugate kit
was used as described in Section 4.1.2.3.
4.1.2. Methods, Results and Discussion
The subtopics within this section deal with the experimental methods related to the
overexpression and detection of the C2 domain, including their results and discussion.
4.I.2.I. Transformation of the C2 plasmid into
E.coli BL21 (DE3) pLysS cells
After verifying the sequencing results for the cloned C2 gene, C2 plasmid and
pET14b (positive control) were used separately to transform BL21 (DE3) pLysS cells as
described in the following protocol.
(1) Two aliquots each of 100 /d of BL21 (DE3) pLysS competent cells were taken out from a
-80 C freezer and thawed on ice.
(2) The cells were then gently mixed and were taken into two 14-ml falcon polypropylene
round-bottom tubes.
(3) 1.7 ill of the /3-mercaptoethanol was added to each of the polypropylene tubes to its final
concentration o f 25 mM. Then the tubes were gently swirled.
(4) The tubes were incubated on ice for 10 min swirling gently every two min.
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(5) Next, about 10 pi of C2 plasmid and 1 pi of pET14b (50 ng/pl) were added to the two
tubes separately and gently swirled.
(6) Then both the tubes were incubated on ice for 30 minutes. During this time, the SOC
medium supplied with the kit was preheated in a water bath at 42°C.
(7) After that, each of the two transformation reactions was heat-pulsed in the water bath at
42°C for 45 seconds. Then they were incubated on ice for 2 minutes.
(8) Then, 0.9 ml of the preheated SOC medium from step 6 was added to each of the
transformation reactions and then both the tubes were kept shaking at 37°C for 1 hr at 225
rpm.
(9) After that 200 pi of cells from each of those transformation reactions were spread onto
two separate LB agar plates containing ampicillin (50 pg/ml) and chloramphenicol (34
pg/ml).
(10) The plates were then incubated at 37°C overnight for 15 hours and were inspected for
the colonies thereafter.
About 30 colonies were formed on the plate that was plated with C2 transformed cells,
while there were about 50 colonies on the positive control plate that was plated with pET14b
transformed cells. Six random colonies were picked from the C2 transformed plate and were
used to inoculate six different flasks containing fresh LB broth cultures. A single random
colony was also picked from the pET14b transformed plate and was used to inoculate a flask
containing fresh LB broth culture. Each of those flasks contained 50 ml of LB broth culture
including ampicillin and chloramphenicol at concentrations of 50 pg/ml and 34 pg/ml
respectively. Then those flasks were kept shaking at 37°C for 15 hours at 225 rpm. The next
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day, all the seven flasks were observed for bacterial cell growth. As all had bacterial growth
in them, 50% glycerol stocks were made for each of those seven cultures and were stored at
-80°C in a freezer.
4.I.2.2. Overexpression of the C2 domain gene
From one of the six C2 glycerol stocks, a small quantity of C2 transformed cells was
used to inoculate a fresh 100 ml culture of LB broth containing ampicillin and
chloramphenicol at 50 pg/ml and 34 pg/ml respectively in a 250 ml Erlenmeyer flask. The
flask was then kept shaking at 37°C for 10 hours at 225 rpm. Thereafter, 15 ml of this culture
was used to inoculate a fresh 135 ml culture with required antibiotics contained in another
500 ml Erlenmeyer flask. The resulting 150 ml of culture was kept shaking at 37 °C and its
growth was monitored by periodically measuring its absorbance at 600 nm. When the
absorbance at 600 nm reached 0.5, overexpression of C2 was induced by adding IPTG to a
final concentration o f 0.4 mM to the culture. The shaking was then continued, and the
bacteria were allowed to grow for another 3.5 hours. Samples of 1.5 ml volume from the
culture were taken at 0 hr, 1.5 hr and 3.5 hr post induction times. The cell pellets of the above
samples after centrifugation at 14,000 rpm were stored at -20°C for SDS-PAGE analysis.
A 12% SDS-PAGE was prepared as per the protocol B.8 in Appendix B. To each of
the above post-induction samples, 50 pi of 2x Laemmli sample buffer (62.5 mM Tris-HCl,
pH 6.8, 2% SDS, 25% glycerol, 0.01% Bromophenol Blue, 5% /3-mercaptoethanol) was
added and briefly vortexed. The samples were then heated on a hot plate at 95°C for 5
minutes. After that the supernatant from 0 hr post induction sample was loaded onto Lanes 1
and 2, while the supernatants from 1.5 hr and 3.5 hr post induction samples were loaded onto
Lanes 4-6 and 8-10 respectively. 5 pi of protein mass ladder was also loaded onto each of the
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Lanes 3 and 7. After loading, the gel plate assembly was clamped onto the main
electrophoresis apparatus and the gel tank filled with SDS run buffer (25 mM Tris, 192 mM
glycine, 0.1% SDS). The safety cover was then kept in place and the electrodes were
connected to a power supply. The gel was run at 200 V, 50 mA for about 50 minutes until the
dye front reached the bottom of the gel. Then the gel was taken out and stained in about 50
ml of Coomassie Blue R-250 staining solution (0.1% Coomassie Blue R-250, 40% methanol,
10% acetic acid) for about 10 hours. It was then followed by 3 hours of destaining in the
destaining solution (40% methanol, 10% acetic acid). The gel thus obtained was
photographed and was as shown in Figure 4.3.

Figure 4.3. SDS-PAGE indicating the overexpression of the C2 domain gene. Lanes 1 and 2:
0 hr post-induction; Lanes 3 and 7: mass ladder; Lanes 4, 5 and 6: 1.5 hr post-induction;
Lanes 8, 9 and 10: 3.5 hr post-induction.

Lanes 4-6 and 8-10 clearly show thick overexpressed protein bands slightly below the
25 kDa mark. This result clearly indicated that the 6xHis-tagged C2 domain was over
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expressed. However, more tests were needed at this point to prove that it was expressed at the
right size of 22.92 kDa.
4.I.2.3. Detection of the Histidine tag
by dot blotting
Two 250 ml Erlenmeyer flasks each containing 100 ml of fresh LB broth with
required antibiotics were inoculated separately with glycerol stocks of C2 and pET14b
transformed cells and were kept shaking at 37°C for 12 hours. Then, 15 ml of each of the
resulting cultures was used to inoculate two separate fresh LB broth cultures o f 135 ml each
with required antibiotics. Both the flasks were then kept shaking at 37°C and their cell
growth was monitored as before by measuring the absorbance at 600 nm. When the
absorbance reached 0.5, IPTG to a final concentration of 0.4 mM was added to each of the
two flasks and the cells were allowed to grow for another 3.5 hours. Thereafter the cells for
both C2 and pET14b in batches of 50 ml volumes were harvested by centrifugation at 10,000
rpm and the resulting cell pellets stored at -80°C.
To one o f the cell pellets resulting from 50 ml of overexpressed C2, 250 pi of dilution
buffer for denaturing conditions (8 M urea, 0.1 M NaH 2 P 0 4 , 0.01 M Tris, pH 8.0) was added
and incubated at room temperature for 10 minutes with occasional stirring. The same was
done for one of the cell pellets resulting from 50 ml of overexpressed pET14b. 2 pi each of
the resulting pET14b solution (negative control) was applied at the four comers of a
nitrocellulose membrane, while 2 pi each of the resulting C2 solution was applied in 12 dots
towards its center. The membrane was then dried at room temperature for 10 minutes.
Thereafter, the following protocol was used for the detection of 6xHis-tag.
(1) The membrane was washed twice for 10 min each time with TBS buffer (10 mM
Tris-HCl, 150 mM NaCl, pH 7.5) at room temperature.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

76

(2) Then the membrane was incubated for 1 hr in anti-His HRP conjugate blocking buffer
(3% BSA in TBS buffer) at room temperature.
(3) The membrane was then washed twice for 10 min each time in TBS-Tween/ Triton
buffer (20 mM Tris-HCl, 500 mM NaCl, 0.05% Tween20, 0.2% Triton x-100, pH
7.5) at room temperature.
(4) The membrane was again washed for 10 min with TBS buffer at room temperature.
(5) Then the membrane was incubated in Anti-His HRP conjugate solution (1/10001/2000 dilution of conjugate stock solution in blocking buffer) at room temperature
for 1 hr.
(6) The membrane was then washed twice for 10 min each time in TBS-Tween/Triton
buffer at room temperature.
(7) The membrane was washed again for 10 min in TBS buffer at room temperature.
(8) The membrane was then stained with HRP staining solution until the signal was
clearly visible. HRP staining solution was prepared by dissolving 18 mg o f 4-chloro1-naphthol in 6 ml of methanol and then adding it to 24 ml of lx Tris saline (lOx Tris
saline: 9% (w/v) NaCl in 1M Tris-HCl, pH 8.0) followed by further addition of 60 pi
of H 2 O2 .
(9) The chromogenic reaction was then stopped by rinsing the membrane twice with
water.
(10) The membrane was then dried and photographed soon after.
The photograph of the membrane taken thereafter is as shown in Figure 4.4. Only the
dots corresponding to C2 have been induced a color change. This result indicated the
presence o f 6xHis-tag in the over expressed protein.
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Figure 4.4. Nitrocellulose membrane after the dot blot procedure. The 12 dots corresponding
to the over expressed histidine-tagged C2 domain yielded a color change. The 4 dots
corresponding to the overexpressed pET14b (negative control) did not yield any color
change.

4.2. Purification of the C2 Domain
4.2.1. Introduction
The subtopics within this section cover the theory and background information
relating to the procedures involved in the purification of the C2 domain of human tensin.
4.2.1.1. Inclusion bodies
Recombinant proteins expressed in E.coli are often deposited in the form of insoluble
aggregates called inclusion bodies. High levels of protein expression lead to an increase in
the concentration of the nascent polypeptide chains which in turn induces the formation of
inactive aggregates. Reducing the level of gene induction and fermentation of transformed
cells under reduced growth temperature are generally done to increase the yield of native,
soluble and active protein. The formation of inclusion bodies on the whole is determined by a
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combination o f factors such as rates of folding, aggregation, and protein synthesis, the
solubility and thermodynamic stability of folding intermediate and the native states, the
susceptibility to proteolytic degradation and the interaction with chaperones [97]. As such it
is difficult to predict whether a protein would be expressed in soluble fraction or isolated in
inclusion bodies. Though considered as a major obstacle in the production of active soluble
proteins, inclusion body formation has certain advantages. First, the formation of inclusion
bodies normally protects the gene product from host-cell proteases. Also, the product is
inactive and cannot harm the host cell, often giving high expression levels. Furthermore, the
dense inclusion bodies can be readily recovered by centrifugation and a relatively high purity
and degree of concentration of the gene product are obtained after solubilization.
The process of solubilization aims at the formation of no or minimum non-native
intra- or inter-chain interactions, a schematic of which is shown in Figure 4.5. The choice of
solubilizing agents— e.g., urea, guanidine hydrochloride, or detergents— plays a key role in
solubilization efficiency, in the structure of the protein in denatured state, and in subsequent
refolding. Urea and guanidine hydrochloride lead to a flexible and disordered structure of
proteins. Typically, 6-8 M urea and 6-7 M guanidine hydrochloride are required to
completely unfold and solubilize the proteins. Even at the highest concentration of the
denaturant, intra- and inter-molecular interactions can occur. Such a non-native structure can
lead to aggregation or misfolding upon the removal of denaturant.
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Figure 4.5. Non-native intra- and inter-molecular interactions [97].

4.2.I.2. Protein purification pathway
A typical protein purification process follows the pathway as depicted in Figure 4.6.
The pathway taken for the purification process of the 6xHis-tagged C2 domain from E.coli is
shown in the same figure involving only those processes marked with dots.
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Figure 4.6. Protein purification pathway. Copyright: Pierce Biotechnology, Inc.

4.2.I.3. Immobilized metal affinity
chromatography (IMAC)
IMAC is one o f several different chromatographic techniques used in the purification
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are used to bind proteins selectively

by reaction with the imidazole groups of histidine residues, thiol groups of cysteine residues
and indole groups of tryptophan residues. The immobilization of protein involves the
formation of coordinate bond that must be sufficiently stable to allow protein attachment and
retention during the elution of non-binding contaminating material. The subsequent release of
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the protein can be achieved either by simply lowering the pH, thereby destabilizing the
protein-metal complex, or by the use of complexing agents such as EDTA [95].
For the purification of the 6xHis-tagged C2 domain, Ni-NTA technology has been
used.

In this, nitriloacetic acid (NTA) bound to the chromatographic matrix acts as a

chelating ligand. It occupies four of the six ligand binding sites in the coordination sphere of
the nickel ion. The other two sites are free to interact with the 6xHis tag as seen in Figure 4.7.
The 6xHis tag binds strongly to the immobilized nickel ion. For optimal performance, both
the 6xHis tag-nickel and the nickel-NTA interactions are important [98].
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Figure 4.7. Interaction between neighboring residues in the 6xHis tag and Ni-NTA matrix
[98]

Before an IMAC procedure is attempted, it is important to determine whether the
recombinant protein is expressed in soluble form or in insoluble aggregates called ‘inclusion
bodies’. The interaction between Ni-NTA and the 6xHis-tag of the recombinant protein does
not depend on tertiary structure, and hence proteins can be purified either under native or
denaturing conditions. If the protein is found soluble, then there is a higher potential for
binding of background contaminants than under denaturing conditions. The imidazole ring is
a part of the structure of histidine as shown in Figure 4.8, and the imidazole rings in histidine
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residues of the 6xHis-tag bind to the nickel ions immobilized by the NT A groups on the
matrix. Imidazole itself can bind to the nickel ions and disrupt the binding of dispersed
histidine residues in nontagged background proteins. At low imidazole concentrations,
nonspecific, low-affinity binding of background proteins is prevented, while 6xHis-tagged
proteins still bind strongly to the Ni-NTA matrix. Therefore, adding imidazole at low
concentrations of 10-20 mM to the lysis and wash buffers lead to greater purity in fewer steps
[98],

HfN-CH-COCP

CL

Im idazole

Histidine

Figure 4.8. Chemical structures o f imidazole and histidine [98].

Copurification of host proteins that may have formed disulphide bonds with the
protein o f interest during cell lysis can be prevented by adding low levels of /3mercaptoethanol (up to 20 mM) in the lysis buffer. Detergents such as Triton X-100 and
Tween20 (up to 2%), or high salt concentrations (up to 2 M NaCl) can also be added to
reduce nonspecific binding to the matrix caused by hydrophobic or ionic interactions. If the
protein is found insoluble, then strong denaturants such as 6 M GuHCl or 8 M urea are added
to completely solubilize inclusion bodies and 6xHis-tagged proteins. Under these denaturing
conditions, the 6xHis-tag on the protein will be fully exposed so that it’s binding to the NiNTA matrix will improve, and thereby the efficiency of the purification procedure will be
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maximized by reducing the potential for nonspecific binding. The histidine residues in the
6xHis-tag have a pKa of approximately 6.0 and will become protonated, if the pH is reduced
to the range 4.5-5.3. Under these conditions, the 6xHis-tagged protein can no longer bind to
the nickel ions and will dissociate from the Ni-NTA resin. Similarly, if the imidazole
concentration is increased to 500 mM, the 6xHis-tagged proteins will also dissociate because
they can no longer compete for the binding sites on the Ni-NTA resin. Also, reagents such as
EDTA, chelate nickel ions and remove them from the NTA groups. This causes the 6xHistagged protein to elute as a protein-metal complex [98].
4.2.I.4. Cleavage of the Histidine tag
Cleavage of the fusion tag from recombinant protein is critical if the produced protein
is intended to be used as a therapeutic product or if the protein is aimed to be used for
structural determination by X-ray crystallography. In most cases, there is hardly any need for
the affinity tag to be removed. Thrombin is an endoprotease which converts fibrinogen to
fibrin and hence functions as a blood clotting factor. It is also one of the most active sitespecific proteases, and a very low mass ratio of enzyme-to-target protein is needed for
efficient cleavage. The cleavage frequently occurs after the proline-arginine residue pair
when properly exposed in a three-dimensional structure [98]. For the cleavage o f 6xHis-tag
from the C2 domain, restriction grade thrombin from Novagen was used. It was functionally
tested for the specific cleavage of the sequence LeuValProArg JGlySer found in other
recombinant proteins.
4.2.2. Methods, Results and Discussion
The subtopics within this section deal with the experimental methods related to the
purification of the C2 domain including their results and discussion.
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4.2.2.1. Inclusion body test
The 6xHis-tagged C2 domain was over expressed in a 500 ml Erlenmeyer flask to a
final volume of 250 ml similar to the procedure as described in Section 4.1.2.2. The resulting
culture was taken into five 50 ml centrifuge tubes and was centrifuged at 10,000 rpm for 15
minutes. To the cell pellets resulting from two of the tubes, 4 ml of cold isolation buffer was
added to each o f them and vortexed. Then they were sonicated on ice for 2 minutes. After
that both the tubes were centrifuged at 10,000 rpm for 15 minutes. The resulting supernatant
and cell pellet were analyzed on a 12% SDS-PAGE gel as did before. The gel thus obtained
is as shown in Figure 4.9. From the gel picture, high intensity bands in Lane 2 confirm that
the 6xHis-tagged C2 domain was expressed mostly in inclusion bodies.

flbr

Figure 4.9. Polyacrylamide gel indicating the C2 inclusion body test results. Lane 1:
supernatant, Lane 2: cell pellet and Lane 3: mass ladder.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

85

4.2.2.2. Affinity chromatography
of the C2 domain
After identifying that the 6xHis-tagged C2 domain was being expressed in the E.coli
inclusion bodies, a suitable protocol involving their solubilization and purification was
adopted as mentioned below. Initially 6xHis-tagged C2 was overexpressed in an 1 liter
Erlenmeyer flask to a final volume of 500ml as before. Samples at post induction times of 0
hr, 1 hr, 2.5 hr and 3.5 hr were taken out for SDS-PAGE analysis. After 3.5 hr, cells were
harvested by taking the entire culture volume into four 50 ml centrifuge tubes several times
and centrifuging them at 7,000 rpm. Next, to each o f the cell pellets resulting from 125 ml of
culture, the following protocol was adopted.
(1)

The cell paste was resuspended in 5 ml of resuspension buffer (20 mM Tris-HCl, pH
8.0) along with 50 pi o f protease inhibitor cocktail mix.

(2) The cells were then disrupted with sonication on ice at 4 x 10 sec.
(3) Then they were centrifuged at 12,000 rpm for 10 min at 4°C.
(4)

The resulting cell pellet was resuspended in 4 ml of cold isolation buffer (20 mM TrisHCl, 2 M urea, 0.5 M NaCl, 2% Triton X-100, pH 8.0) and was sonicated as above.

(5)

Then they were centrifuged at 12,000 rpm for 10 min at 4°C.

(6)

Steps 4 and 5 were repeated.

(7)

To the resulting cell pellets from all the tubes, 10 ml of solubilization buffer (20 mM
Tris-HCl, 6 M GuHCl, 0.5 M NaCl, 10 mM imidazole, 1 mM /3-mercaptoethanol, pH
8.0) was added along with 200 pi of DNasel (10 pg/ml) and was stirred for 30-60 min.
on a rocker platform at room temperature.

(8)

Then they were centrifuged for 15 min at 12,000 rpm at 4°C.
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(9)

The particulate matter was removed by passing the sample through a 0.45 pm filter.

(10) The sample was degassed for 5 minutes.
Next, a 5 ml His-Trap HP column was connected to the AKTA prime instrument and
was then equilibrated with 50 ml of solubilization buffer. The sample obtained from step 10
above was then loaded onto the column. After loading the sample, 50 ml of solubilization
buffer was passed through the column again to get a steady baseline in the absorbance
reading of the instrument at 280 nm. Thereafter, the instrument was auto-zeroed and 50 ml of
refolding buffer (20 mM Tris-HCl, 6 M urea, 0.5 M NaCl, 5 mM imidazole and 1 mM /3mercaptoethanol, pH 8.0) was passed through the column. Then, an on-column refolding of
the bound C2 domain was attempted by making use of a linear 6-0 M urea gradient, starting
with the refolding buffer above and finishing with the wash buffer. A gradient volume of 100
ml and a flow rate o f 1 ml/min were used. After the gradient has reached its end point, 30 ml
o f wash buffer (20 mM Tris-HCl, 0.5 M NaCl, 10 mM imidazole, 1 mM /3-mercaptoethanol,
pH 8.0) was continued to pass through the column. Next, the elution of the bound C2 domain
was attempted by using a 50 ml linear gradient at a flow rate of 2 ml/min starting with wash
buffer and ending with elution buffer (20 mM Tris-HCl, 0.5 M NaCl, 0.5 M imidazole, 1 mM
/3-mercaptoethanol, pH 8.0). At the start of the elution gradient, a sharp peak was seen on the
chart recorder paper corresponding to an absorbance of 1.0 at 280 nm. During this time, 20
ml of the eluted protein was collected in a 50 ml centrifuge tube. This eluted protein was then
dialyzed twice against 4 liters of 25 mM sodium phosphate, 10 mM NaCl, 1 mM (3mercaptoethanol, pH 7.8. Thereafter 20 pi of this dialyzed protein was analyzed on a 12%
SDS-PAGE gel alongside post-induction samples. The gel was then run at 200 V at 50 mA
for 45 minutes. After staining and destaining procedures, the gel obtained is as shown in
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Figure 4.10. Lanes 6 and 7 of the gel clearly show good intensity bands of purified C2
domain at around 23 kDa size. This result indicates that the purification of the C2 domain has
been done successfully.

Figure 4.10. Polyacrylamide gel confirming the purification of the C2 domain. Lanes 1, 2, 3
and 4: 0 hr, 1 hr, 2.5 hr and 3.5 hr post induction respectively; Lanes 5: mass ladder; and
Lanes 6 and 7: purified 6xHis-tagged C2 domain.

4.2.2.3. Cleavage of the Histidine tag
of the C2 domain
The remaining dialyzed C2 protein from the above experiment was taken into five 5
ml vials and was freeze dried using a lyophilizer. To the freeze dried C2, DI water was added
to get a final concentration of 1 pg/pl. Restriction grade thrombin was used to cleavage the
6x His tag. Five different thrombin cleavage reactions each of 50 pi total volume were setup
in tubes 1, 2, 3, 4 and 5 as shown in Table 4.1.
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Table 4.1. Thrombin cleavage reaction components for the His-tagged C2 domain.
Tube-2

Tube-3

Tube-4

Tube-5

5 pi

5 pi

5 pi

5 pi

5 pi

lp l

2 pi

3 pi

4 pi

2 pi

DI water

41 pi

40 pi

39 pi

38 pi

41 pi

C2 domain

3 pi
(i ng/ni)

3 pi
(1 Jig/til)

Control protein

-

-

Tube-1
lOx Thrombin
cleavage buffer
1:25 diluted
thrombin

3 pi
3 pi
(1 Fg/pl) (i ng/pi)
-

-

2 pi
(1 Jig/Hl)

Tube 5 was a positive control in which a 48 kDa control protein was used. Successful
cleavage o f this protein with thrombin would yield two protein fragments at sizes 35 kDa and
13 kDa. All the above tubes were then incubated at room temperature for 24 hours. Then to
each o f the tubes 1, 2, 3 and 4, 2 pi of C2 was added and were analyzed by running them on a
12% SDS-PAGE as before. The gel obtained after the staining and destaining procedures is
as shown in Figure 4.11.
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Figure 4.11. Polyacrylamide gel showing the cleavage of 6xHis-tag from the recombinant
C2 protein using variable amounts of thrombin. Lanes 1 & 2, Lanes 3 & 4, Lanes 6 & 7, and
Lanes 8 & 9: thrombin cleavage of C2 with 1 pi, 2 pi, 3 pi and 4 pi of 1:25 diluted thrombin;
Lane 5: mass ladder and Lane 10: thrombin cleavage of the control protein with 3 pi of 1:25
diluted thrombin.

Lanes 1-4 and 6-9 clearly indicate thrombin cleavage yielding a cleaved C2 at 20.5
kDa along with the uncleaved C2 at 22.9 kDa. One of the cleaved fragments of the control
protein at 35kDa can also be seen in the positive control Lane 10. Hence from this
experiment, we can conclude that the purified 6xHis-tagged C2 protein has an accessible
histidine tag that can be successfully cleaved by thrombin to yield the desired C2 domain.
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CHAPTER 5
REFOLDING AND BIOPHYSICAL
CHARACTERIZATION
OF THE C2 DOMAIN
5.1. Introduction
This section contains subtopics covering the theory and background information
relating to the procedures involved in the refolding and biophysical characterization of
the C2 domain of human tensin.
5.1.1. Protein Refolding
Refolding is a process that leads to conformation change from unfolded (inactive)
state to folded (active) state. At high denaturant concentrations, proteins are unfolded,
well solvated, and flexible. But in aqueous buffers, they are folded, rigid and compact.
Generally, transfer of protein molecules from denaturant solution to aqueous solvent will
force them to collapse into a compact structure. But such a drastic process usually leads
to misfolding and aggregation. Once misfolded or aggregated, in the absence of
denaturants, proteins have no flexibility to disaggregate and refold into the native
structure. A key to refolding is in the intermediate concentration of the denaturant of the
denaturant, where denaturant is low enough to force protein molecules to collapse, yet
can allow them to stay in solution and be flexible to reorganize their structures. However,
which intermediate concentration works depends on the proteins and how the denaturant
concentration is reduced. Intermediates have structures that are unstable and less soluble.
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As such they readily misfold and aggregate. It is therefore important to facilitate folding
of the intermediate into the more stable native structure (N), yet maintain the solubility
and flexibility of the intermediate (See Figure 5.1).

AGGREGATE

MISFOLD/AGGREGATE

Figure 5.1. Schematic diagram o f refolding course. U, I, and N correspond to the
unfolded, intermediate, and native state of protein, respectively [97],

Optimal refolding can be achieved by forcing the denatured protein to collapse
but still maintain its solubility and flexibility, and this is done by the way by which
denaturant concentration is reduced. How fast the denaturant is reduced and how long the
protein molecules are exposed to intermediate denaturant concentration determines the
rate of folding and the degree of flexibility or solubility of folding intermediates. In
addition, the rate of folding vs. misfolding or aggregation can be manipulated by small
molecule additives. Certain additives enhance structure formation or collapse, while
others increase flexibility or solubility of proteins.
5.1.1.1. Dialysis
In one-step dialysis, the denatured and unfolded protein molecules in the
concentrated denaturant solution are dialyzed against a refolding buffer containing much
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less or no denaturant. As such, the protein solution is exposed to a descending
concentration of the denaturant and the denaturant concentration within the dialysis bag is
decreased with time to the concentration of the refolding buffer. As the concentration of
denaturant is decreased, the rate of folding into the intermediate and native structure
increases. However, the rate of misfolding or aggregation also increases. There is also a
high chance o f aggregation, if the protein concentration is high in the dialysis tubing.
This aggregation is due to the reasons that the protein concentration remains relatively
constant within the tubing through the process and also as the denaturant concentration is
slowly decreased, the interaction of hydrophobic patches is quite fast due to the high
concentration o f protein. Hence the initial protein concentration in the denaturant is
critical. Also, if the rate of folding is slow, there is a greater chance for aggregation
because the moderate to low concentration may not be enough to keep the unfolded or
intermediate structures soluble.
In step-wise dialysis, the unfolded protein sample is first brought to equilibrium
with high denaturant concentration, then with middle concentration, and with low
concentration. In contrast to one-step dialysis, here the equilibrium is established at each
denaturant concentration.
5.1.1.2. Dilution
In dilution, protein samples at high denaturant concentration are delivered into a
large volume of refolding buffer. This process induces a rapid collapse in the unfolded
sample bypassing the intermediate denaturant concentration. Here, both the denaturant
and protein concentrations increase as the unfolded protein in concentrated denaturant is
delivered into the refolding buffer.
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In pulsed dilution, after an aliquot o f the denatured protein solution is diluted into
the refolding buffer, refolding is allowed to occur for some period before adding the next
aliquot. As such this avoids the accumulation of high concentration of folding
intermediates that occur in one-step dilution.
5.1.1.3. Role of co-solute assistance
Co-solutes are classified into folding enhancers and aggregation suppressors.
Folding enhancers enhance protein-protein interactions, while aggregation suppressors
reduce side chain interactions and association o f folding intermediates without interfering
with refolding process. Polyethylene glycol, cyclodextran, L-arginine, and proline are a
few examples of aggregation suppressors. L-arginine is the most frequently used co
solute, but how it reduces aggregation of folding intermediates is unclear. However,
studies by Reddy et al. demonstrated that L-arginine seems to increase the equilibrium
solubility o f unfolded and intermediate states of hen egg white lysozyme during refolding
[99]. The use o f L-arginine and pulsed dilution has been moderately successful in the
refolding experiments of the C2 domain as described in Section 5.2.2.
5.1.2. Circular Dichroism (CD)
Spectropolarimetrv
Circular dichroism is mainly used for studying changes in the secondary and
tertiary structure of proteins. There are two requirements for a molecule or a group of
atoms in a molecule to exhibit a circular dichroism (CD) spectrum. The first is the
presence of a chromophore i.e., a group that can absorb radiation by virtue of the
electronic configuration of its ground state at room temperature. The energy absorbed
results in a transition to a higher-energy or excited state, which has a different
distribution o f electrons around the nucleus. It can therefore interact with its environment
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in a way that differs from the ground state. In proteins, Tryptophan, Tyrosine and Phenyl
alanine are the main chromophores in the near-UV (240- to 320-nm), while the peptide
bond is the main chromophore in the far-UV (180- to 240-nm). The second requirement
for a CD is that the chromophore be present in an optically asymmetric environment
[100],
Plane polarized radiation consists of two circularly polarized vectors of equal
intensity, one right handed and the other left handed as shown in Figure 5.2, which are
separately measured in the CD spectrometer by a photoelastic modulator. A chromophore
situated in an optically symmetric environment will normally absorb the two components
equally so that, when recombined after passing through a solution of the chromophore,
they result once again in radiation oscillating in a single plane. A chromophore situated in
an optically asymmetric environment, however, will absorb each of the two components
to a different extent, the difference being AA. The resultant radiation would now be
elliptically polarized i.e., the resultant would trace out an ellipse. The dichroism at a
given wavelength of radiation is expressed as either the difference in absorbance of the
two components (AA=

A

l- A r )

or as the ellipticity in degrees (6). (6 = tan‘'(b/a), where

‘b ’ and ‘a’ are the minor and major axes of the resultant ellipse.
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A

B

Figure 5.2. The relation of ellipticity to the differential absorption of circularly polarized
radiation. (A) Plane-polarized radiation, made up of left- and right-circularly polarized
components, OL and OR respectively (B) Interaction of radiation with a chiral
chromophore leads to unequal absorption causing the emerging vectors OL’ and OR’ to
describe an elliptical path [101].

In the far-UV, the peptide bond is the principal absorbing group and studies in
this region can give information on the secondary structure. In the near-UV, the aromatic
amino acid side chains (phenyl alanine, tyrosine and tryptophan) absorb in the range of
250-290 nm. The tertiary folding of the polypeptide chain can place these side chains in
chiral environments, thus giving rise to CD spectra which can serve as characteristic
fingerprints of the native structure.
5.1.3. Differential Scanning
Calorimetry (DSC)
A protein in aqueous solution is in equilibrium between the native (folded)
conformation and its denatured (unfolded) conformation, therefore, Kunf= [U]/[N]. where
[U] is the concentration of unfolded protein, [N] is concentration of native protein, and
Kunf is the equilibrium constant between native and denatured protein. The stability of the
native state is based on the magnitude of Gibbs free energy (AG) in the thermodynamic
relationships AG=AH-TAS and AG=-RTlnKunf. Where AH is the enthalpy change and AS
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is the entropy change. A positive AG indicates the native state is more stable than the
unfolded state. The higher the AG, the greater the stability. Protein stability depends on
the balance between enthalpic changes (due to changes in hydrophobic interactions and
hydrogen bonding) and entropic changes (due to solvation and conformational freedom).
For a protein to unfold, stabilizing forces need to be broken. Conformational entropy
weakens stabilizing forces allowing the protein to unfold at high temperature where the TAS term becomes dominant [101].
A DSC measures the AH of protein folding due to heat denaturation. In a DSC
instrument, a protein solution and a reference solution are in matched cells, and heated at
a constant rate. The power input into the sample solution is compared to the power
required to raise the temperature of the reference solution. If the protein in the sample cell
undergoes thermal unfolding from a low-temperature native state to a high-temperature
denatured state, this process is prominently seen in the resulting plot o f differential power
vs. temperature.
The unfolding transition is recognized as a sharp endothermic peak centered at a
characteristic temperature called the transition midpoint (Tm). By integrating the area
under the peak, the heat of unfolding (AH) can be determined. Tm is an indicator of
thermostability and in general, the higher the Tm, the more stable the protein. DSC also
measures the change in heat capacity (ACP) of a protein during denaturation. The ACP for
protein unfolding is almost positive, because a denatured protein has a higher heat
capacity than a native protein. Heat capacity changes associated with protein unfolding
are primarily due to changes in hydration of side chains that were buried in the native
state, which become solvent-exposed in the denatured state.
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5.2. Methods, Results and Discussion
The subtopics within this section deal with the experimental methods related to
the refolding procedures o f the C2 domain, its biophysical characterization along with
their results and discussion.
5.2.1. Protein Preparation for
Biophysical Studies
About 20 ml of purified C2 protein fractions obtained from one of the affinity
chromatography procedures (described in Section 4.2.2.2) was taken into a dialysis
tubing o f 10 kDa cutoff. The protein was dialyzed for 4 hours against 4 liters o f 25 mM
sodium phosphate, 10 mM NaCl, 1 mM /3-mercaptoethanol, pH 7.8 contained in a glass
beaker. After 4 hours, buffer was changed with a freshly prepared one and the dialysis
was continued overnight. After dialysis, the protein was recovered from the dialysis
tubing and was concentrated using 10 kDa cutoff centricon filters. The concentration of
the C2 protein thus obtained was then measured to be 1.062 mg/ml by measuring the
absorbance at 280 nm.
Next, 3.5 ml o f the phosphate buffer from the centricon filtrates, resulting from
the above procedure, was taken into a 1 cm path length cuvette and its baseline CD
spectrum was measured in the near-UV range of 250 nm-360 nm. 120 scans were
performed. Thereafter, 3.5 ml of the C2 protein was taken into the cuvette, and its nearUV CD spectrum was measured in the same wavelength range with the same number of
scans. The spectrum thus obtained after baseline subtraction is as shown in Figure 5.3.
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Figure 5.3. Near-UV CD spectrum of the C2 domain in 25mM phosphate buffer, pH 7.8.

The near-UV spectrum of the C2 domain as depicted in Figure 5.3 has no
aromatic asymmetry signifying any amount of tertiary structure. However, the protein
was used to do some far-UV experiments as follows.
Next 300 ml of 250 mM sodium phosphate, 100 mM NaCl, 10 mM /?mercaptoethanol, pH 7.8 (lOx buffer) was prepared to be used for guanidine
hydrochloride (GuHCl) CD titration experiments in the far-UV. Samples for the far-UV
GuHCl CD titration points of 0 M, 0.5 M and 1 M were prepared by mixing the
respective components as depicted in Table 5.1 and were incubated for 1 hour. The
corresponding baseline samples were also prepared replacing 30 pi of protein with the
buffer.
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Table 5.1. Sample compositions for the far-UV GuHCl titration points of 0 M, 0.5 M and
1 M in 25 mM sodium phosphate buffer, pH 7.8.

0M

0.5 M

1M

lOx buffer

30 pi

30 pi

30 pi

C2 protein

50 pi

50 pi

50 pi

8 M GuHCl

Opl

18.75 pi

37.5 pi

d i -h 2o

220 pi

201.25 pi

182.5 pi

Total

300 pi

300 pi

300 pi

It was observed that the C2 protein got precipitated in the 0.5 M and 1 M vials
soon after their preparation. However, for each of the above three points, CD spectra
were measured, both for the baseline and C2 samples in the far-UV wavelength range of
190 nm-260 nm. A 1-mm path length quartz cuvette was used for the same. The far-UV
baseline subtracted CD spectra of each of these points are overlaid and are as shown in
Figure 5.4.
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Figure 5.4. Far-UV CD spectra of the C2 domain in 25 mM phosphate buffer, pH 7.8 for
0 M, 0.5 M and 1 M GuHCl titration points.

It can be seen that for the 0.5 M and 1 M titration points, the CD spectra yielded
near zero signals; the reason being the C2 protein getting precipitated out of the solution
from these samples. These results for the C2 domain along with its near-UV CD
spectrum in Figure 5.5 indicate that the protein may be partly folded with very low
tertiary structure. Another reason assumed for the protein precipitation might be the
experimental pH of 7.8 which is close to the isoelectric point of 6.29. The isoelectric
profile for the C2 domain for both the tagged and untagged versions is as shown in Figure
5.5.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

101

40
C2-with-His-T ag
C2-without-H is-T ag

©

O)
n

-10

-20

-30
-40
0

2

4

8

6

10

12

14

pH

Figure 5.5. Isoelectric profile of the C2 domain with or without histidine tag. The
histidine tagged version has a p / of 6.29, while that of the other has 5.81.

In an attempt to prevent the precipitation an alternative buffer, i.e., a carbonate
buffer with a pH of 9.6 was sought. 300 ml of 250 mM sodium carbonate, 100 mM NaCl,
10 mM jS-mercaptoethanol, pH 9.6 (lOx buffer) was prepared to be used for the far-UV
GuHCl CD titration experiments. Samples for the far-UV CD GuHCl titration points of 0
M and 0.5 M were prepared just as before as per the Table 5.1 and were incubated for an
hour. This time also it was observed that the protein got precipitated in the 0.5 M sample.
But still the spectra for the 0 M and 0.5 M samples were measured as before. The
resulting spectra are overlaid and are as shown in Figure 5.6.
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Figure 5.6. Far-UV CD spectra of the C2 domain in 25 mM carbonate buffer, pH 9.6 for
0 M and 0.5 M GuHCl titration points.

From Figure 5.6, it can be seen that the 0.5 M sample yielded a near zero signal.
Hence it was concluded that the cause for the precipitation is not the pH of the buffer, but
rather the protein itself with regard to its stability and folded state after the on-column
refolding procedure. As such various refolding procedures for the C2 domain were
sought as described in Section 5.2.2.
5.2.2. Refolding Trials for the C2 Domain
As the first method to refold the C2 domain, one-step dialysis was sought. In this
method, 3 ml of the C2 protein was completely denatured in 6 M GuHCl. Then 500 ml of
25 mM sodium carbonate, 10 mM NaCl, 50 mM L-arginine, 1 mM /3-mercaptoethanol,
pH 9.6 was prepared. The denatured C2 protein was then dialyzed against the above
prepared buffer for 4 hours. After 4 hours, it was noticed that the protein got precipitated
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in the dialysis bag. However, the buffer was replaced by a freshly prepared one and the
dialysis was continued overnight. In the morning, it was noticed that the protein was still
in precipitated form. Hence an alternative method of step-wise dialysis was sought as
described next.
Here in this method, the C2 protein from the above procedure was denatured
completely in 6 M GuHCl. Then 500 ml of 25 mM Tris, 4 M GuHCl, 100 mM Larginine, 5 mM /3-mercaptoethanol, pH 8.0 was prepared. The denatured protein was
taken into dialysis tubing and was dialyzed against the above prepared buffer for about 4
hours. After 4 hours, the buffer in the beaker was replaced by 500 ml of 25 mM Tris, 2 M
GuHCl, 100 mM L-arginine, 5 mM /3-mercaptoethanol, pH 8.0. The dialysis was
continued overnight. Next morning, the buffer in the beaker was replaced by 500 ml of
25 mM Tris, 1 M GuHCl, 100 mM L-arginine, 5 mM /3-mercaptoethanol, pH 8.0 and the
dialysis was continued for 4 hours. After 4 hours, the buffer in the beaker was replaced
by 500ml of 25 mM Tris, 100 mM L-arginine, 5 mM /3-mercaptoethanol, pH 8.0. The
dialysis was then continued. As soon as the dialysis was started, the C2 protein within the
dialysis tubing began to precipitate out of the solution. However, the dialysis was
continued for another 4 hours. After 4 hours, the precipitated protein from the dialysis
tubing was taken out and stored at +4°C. From the above observations, it was evident that
though the refolding process was slow when the concentration of GuHCl was decreasing
slowly, the interaction between hydrophobic patches among the protein molecules was
quite fast, due to the relatively high concentration of the protein, thus leading to
aggregation. As such, an alternative refolding method of pulsed dilution was sought as
described next.
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In this method, the C2 protein from the above procedures was solubilized and
denatured in 6 M GuHCl. To this solution, L-arginine to a final concentration of 100 mM
was also added. Thereafter, the protein was concentrated by 10 kDa cut-off centricon
filters to a final volume of about 1 ml. 25 ml of 25 mM sodium carbonate, 500 mM Larginine, 10 mM NaCl, 1 mM /3-mercaptoethanol, pH 10.0 was prepared in a glass beaker
o f 120 ml volume. To this buffer, 1 ml of the concentrated C2 protein was added drop
wise slowly with rapid stirring. Thereafter, the diluted protein solution was taken into two
dialysis tubings and was dialyzed overnight against 3 liters of 25 mM sodium carbonate
buffer, 10 mM NaCl, 1 mM /3-mercaptoethanol, pH 9.6. Next morning the protein from
the dialysis tubings was taken out and was concentrated using 10 kDa cut-off centricon
filters. After concentrating the protein to a volume of about 4 ml, its concentration was
estimated to be 1.063 mg/ml.
5.2.3. Near-UV CD Measurement of the
C2 Domain after Refolding
Next, about 3.5 ml of buffer from the filtrate of the centricon filters above was
taken in a quartz cuvette of 1 cm path length and its near-UV baseline CD spectrum was
measured in the wavelength range of 250 nm-360 nm. In all, 150 scans were performed.
After that, 3.5 ml of the concentrated C2 protein was taken into the cuvette and its nearUV CD spectrum was measured in the same wavelength range with the same number of
scans. The spectrum thus obtained after baseline subtraction and normalizing for protein
concentration is as shown in Figure 5.7.
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Figure 5.7. Near-UV CD spectrum of the C2 domain in 25 mM carbonate buffer, pH 9.6
after refolding by pulsed-dilution procedure.

From Figure 5.7, the shoulders seen at around 268 nm and 289 nm can be
attributed to the 21 aromatic residues (12 Phenyl alanines, 1 Tryptophan and 8 Tyrosines)
present in the 6x His-tagged C2 domain. The aromatic asymmetry of the spectrum thus
indicates that some of the protein molecules are folded or partly folded.
5.2.4. Far-UV CD Measurements of the
C2 Domain after Refolding
After attempting to refold the C2 domain by pulsed dilution, the following CD
titration experiments were done in the far-UV range.
5.2.4.I. GuHCl titration experiments
Using the same refolded protein preparation, far-UV GuHCl CD titration
experiments were performed for the points from 0 M to 6 M for every 0.25 M increment.
Totally 80 scans were performed both for the baseline and actual C2 samples. It was
observed that there was some precipitation of the protein in GuHCl titration samples of
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0.25 M, 0.5 M, 0.75 M and 1 M. But for other samples there was no precipitation at all.
The baseline subtracted and normalized spectra for the 0 M and 6 M titration points are as
shown in Figure 5.8.
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Figure 5.8. Far-UV CD spectra of the C2 domain in 25 mM carbonate buffer, pH 9.6
after the refolding procedure. Solid line: 0 M GuHCl; Dashed line: 6M GuHCl.

C2 domains in general consist of a compact /3-sandwich composed of two fourstranded /3-sheets [79], The CD spectra of /3-rich proteins are classified as /Si or /3n on the
basis of the far-UV CD spectrum. The far-UV CD spectra of /Si proteins resemble those of
model /3 sheets, having a significant positive band around 190 nm and a comparable
negative band in the 210-220 nm region [102, 103], The 0 M spectrum from Figure 5.8
shows a negative band near 208 nm, suggesting a high content of /3 structure as in /3i
proteins. Alternately it can be interpreted that the domain is substantially unfolded under
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the conditions of data collection. The C2 domain is likely to be completely unfolded in 6
M GuHCl because its spectrum closely resembles that of a typical random coil [104].
Some folded structure is present in the absence of GuHCl according to the near-UV
spectrum and the change in the shape of the far-UV spectrum on the addition of GuHCl.
The baseline subtracted and normalized spectra of all the GuHCl titration points from 0
M to 6 M resulting from the same set of experiments are overlaid in Figure 5.9.
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Figure 5.9. Normalized far-UV CD spectra of the C2 domain in GuHCl titration points
from 0 M to 6 M. For the sake of clarity, between the points 2 M and 6 M, only spectra at
every 0.5 M increment are shown.

Chemical denaturation of the domain was also monitored by the change in
ellipticity at 220 nm at various concentrations of GuHCl. Ellipticity at 220 nm as a
function of GuHCl concentration is as shown in Figure 5.10.
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Figure 5.10. Ellipticity at 220 nm as a function o f GuHCl concentration.

From the profile in Figure 5.10, it can be seen that the partial precipitation of the
C2 protein in 0.25 M, 0.5 M, 0.75 M and 1 M GuHCl samples caused a spike, thus
making it hard to interpret the pattern of protein unfolding in GuHCl.
Studies by Edwin and colleagues [105] have shown that for some acidic proteins
for example papain, low concentrations of GuHCl can induce aggregation and that it can
be prevented by the presence of low concentrations of urea in the buffer. In addition,
stabilization of protein can also be induced.
5.2.4.2. Urea titration experiments
Before attempting to do the same for the C2 domain, GuHCl was replaced by urea
to perform the titration experiments. As such, all the titration experiments were repeated
with urea as before in 25 mM carbonate buffer, pH 9.6. The baseline subtracted and
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normalized spectra for all the points from 0 M to 6.5 M at every 0.5 M of urea
concentration are superimposed and are shown in Figure 5.11.
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Figure 5.11. Normalized far-UV CD spectra of the C2 domain in urea titration points
from 0 M to 6 M.

In this case also, the chemical denaturation was monitored by the change in
ellipticity at 220 nm at various concentrations of urea as shown in Figure 5.12.
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Figure 5.12. Ellipticity curve at 220 nm for the C2 domain as a function of urea
concentration.

The urea denaturation data from Figures 5.11 and 5.12 suggest a gradual
unfolding of the domain. However, the far-UV CD spectrum in 6.5 M urea shows
evidence for some residual structure in the protein. The comparison of the spectra in 6.5
M urea and 6 M GuHCl is as shown in Figure 5.13. The spectrum in 6 M GuHCl very
closely resembles that o f a random coil, while that of 6.5 M urea does not. Hence, it can
be concluded that a mild denaturant like urea would not be appropriate to use to study the
thermostability of the C2 domain.
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Therefore, as initially suggested by Edwin et al. [103], urea was used in the
GuHCl titration experiments to get around with the problem of protein precipitation.
5.2.4.3. GuHCl titration experiments
with low amounts of urea
All the GuHCl titration experiments are repeated with 0.5 M urea added to 0.5 M,
1 M, 1.5 M and 2 M GuHCl samples. When these samples were observed after 1 hour
incubation, there was no precipitation of the protein at all. Next, the CD experiments
were performed in the far-UV range as before. The baseline subtracted and normalized
spectra from 0 M to 6 M GuHCl points are as shown in Figure 5.14.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

112

OM-GuHCI

5000 -i

0.5M-GuHCI/0.5M-Urea
1M-GuHCI/O.SM-Urea
1.5M-GuHCI/0.5M-Urea
2M-GuHCI/0.5M-Urea
2.5M-GuHCI

15000

3M-GuHCI

20000

3.5M-GuHCI
4M-GuHCI

E -25000

4.5M-GuHCI

2 -30000

5M-GuHCI

x. -35000

5.5M-GuHCI

® -40000

6M-GuHCI

-45000
210

220

230

240

250

260

W a v e le n g th (nm )

Figure 5.14. Normalized far-UV CD spectra of the C2 domain in GuHCl titration points
from 0 M to 6 M with low amounts of urea.

From Figure 5.14, a very gradual transition can be seen in the shape of the spectra
from a /3-rich pattern to that of a random coil. Also, the ellipticity curve at 220 nm as a
function of GuHCl concentration is shown in Figure 5.15. It shows a gradual unfolding of
the domain probably signifying the partial folding of the domain in the absence of
denaturant.
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Figure 5.15. Ellipticity curve at 220 nm for the C2 domain as a function of GuHCl
concentration (with low amounts of urea).

5.2.5. Differential Scanning Calorimetry
Experiments
The C2 domain resulting from the pulsed dilution procedure of refolding was used
for a DSC experiment. Initially the buffer alone, i.e., 25 mM sodium carbonate, 10 mM
NaCl, 1 mM j8-mercaptoethanol, pH 9.6 was loaded onto the reference and sample cells
as per the manufacturer’s protocols. Four up-scans were performed from 10°C to 110°C
at a constant heating rate of 30°C per hour. The baseline scans obtained thereafter are
overlaid and are as shown in Figure 5.16.
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Figure 5.16. Overlay of the DSC baseline scans.

After the baseline scans were done, the reference and sample cells were cleaned.
Then the C2 protein in carbonate buffer at 0.8 mg/ml is loaded onto the sample cell,
while carbonate buffer is loaded onto the reference cell. Four scans were performed just
as before in the same temperature range at the same rate of heating. The profiles of the
scans are overlaid and are as shown in Figure 5.17.
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Figure 5.17. Overlay of the DSC C2 scans.

From Figure 5.17, no noticeable endothermic peak could be seen during the heat
denaturation process. This result suggests that the C2 domain was partly unfolded at
room temperature in the absence of chemical denaturant, or unfolding was gradual on
addition of heat. The above possibilities are not mutually exclusive. Indeed, gradual
unfolding at room temperature is suggested by the guanidine denaturation data, probably
signifying the partial unfolding of the domain in the absence of denaturant.
The partial unfolding of the C2 domain in the absence of denaturant can well be
attributed to the reason that the domain naturally tends to get expressed in E.coli
inclusion bodies and hence would indicate the need for the presence of the PTP domain at
its N-terminus in tensin in order to increase its stability just as it is in PTEN.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1. Conclusions
The C2 domain gene of human tensin has been successfully synthesized, cloned
and expressed in E.coli. Overexpressed C2 domain in E.coli inclusion bodies was
successfully isolated and purified. Initially purified protein was tested for its stability by
circular dichroism. Thereafter, various methods have been employed to refold the C2
domain. After the refolding procedures, the protein was further characterized by circular
dichroism and differential scanning calorimetry.
The biophysical characterization results, based on the near-UV CD spectrum and
the change in shape o f the spectra in far-UV GuHCl CD titration experiments indicated
some folded structure in the C2 domain of human tensin. The absence of any endotherm
in the DSC experiments indicates that the domain was partly unfolded at room
temperature in the absence of chemical denaturant, or unfolding was gradual on addition
of heat; the above possibilities being not mutually exclusive. Also, gradual unfolding at
room temperature as suggested by the GuHCl denaturation data probably signifies the
partial folding of the domain in the absence of denaturant. The partial folding of the C2
domain as evident from the experimental results indicates that the C2 domain may be
thermodynamically unstable on its own in solution and hence there is a need for the
presence of the PTP domain at its N-terminus for additional stability. The experimental
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results also reinforce the existence of a C2 domain in tensin which has not been
documented earlier.

6.2. Future W ork
Co-expressing the PTP domain gene linked to 5’ end of the C2 domain gene
might increase the thermostability of the C2 domain and thus make it functional because
PTP-C2 seems to be a common supra-domain structural/functional motif and also that
both the PTP and C2 domain are required for the focal adhesion localization of the Nterminus of tensin. Both the C2 and PTP domain encoding genes can be linked by doing
a PCR on each of the domain genes using primers encoding a Bel I restriction site. This
restriction site is compatible with the amino acid sequence of the linker residues between
the PTP and C2 domains. Following PCR, the products can be digested with Bel I,
purified and ligated. The ligation product can then be amplified by PCR, using end
primers. The resulting gene can thus be purified by agarose electrophoresis, digested with
Nde I and Xho I, and cloned into the pET14b vector.
Anti-sera containing antibodies against the PTP, C2 and PTP-C2 domains can be
prepared by using animals, e.g., rabbits. Since both these domains are in the N-terminus
of tensin, the anti-sera to these domains should be particularly useful for
immunoprecipitating proteins that interact with the C-terminus, i.e., with the SH2
domain, PTP domain and, perhaps, the central region of tensin. Such antibodies will have
a number of advantages over commercial antibodies. They will be more specific for the
corresponding tensin domains than full-length tensin polyclonal antibodies, and they will
probably be more suitable for immunoprecipitation than monoclonal antibodies available
from a commercial source.
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Once the domain or the domain pair is folded, thermostability for the same can be
determined by differential scanning calorimetry as was attempted in this work. This
approach enables a direct measurement of AH of the domain/domain-pair unfolding due
to heat denaturation. Heat o f unfolding (AH) can be determined by integrating the area
under the peak (AHcai)- This will be compared with the computed van’t Hoff enthalpy
(A H v h )

to assess the cooperativity of denaturation. Heat capacity (ACP) of the

domain/domain-pair can also be measured by DSC, either by non-linear squares fitting of
a 2- or multi-state model to baseline subtracted experimental data, or by measurement of
the heat of unfolding as a function of pH.
Conditions for growing crystals for the domain/domain-pair can be sought. Initial
crystallization conditions can be sought using various crystallization kits, testing a wide
range o f pH, salt concentrations, and precipitants for the highly concentrated protein.
Results from an initial screen will produce crystals or solubility information. When
crystals are obtained, information obtained from the screen will be used to optimize
crystallization conditions to produce crystals suitable for X-ray diffraction analysis.
More detailed knowledge of the structure and function of tensin resulting from the
above kind of experiments for all the domains will lead to a better knowledge of other
focal adhesion components, advancing the development of molecular models of cell
attachment and migration. It provides a rational basis for drug design pertaining to the
cellular processes and can be of commercial value. It will also lead to a better
understanding of the nature of molecular assemblies in cells.
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MATERIALS
All the oligonucleotides were purchased from Syngen, Inc. (San Carlos, CA).
dNTPs, restriction enzymes viz Ndel and Xhol, T4 DNA ligase and Wizard plus
minipreps DNA purification systems were all purchased from Promega (Madison, WI)
while Cloned pfu polymerase and XL2-Blue ultracompetent cells were from Stratagene
(La Jolla, CA). Both QIAquick gel extraction and PCR purification kits were purchased
from Qiagen (Valencia, CA). Agarose and ampicillin were obtained from Bio-world
(Dublin, OH), while LB Broth EZ Mix was from Sigma Aldrich (St.Louis, MO).
All PCR reactions were performed on thermal cycler TC-512 from Techne, Inc.
(Burlington, NJ). All agarose gels were run on Electrophoresis Subsystem-70 from
Labnet International, Inc. (Edison, NJ) and were visualized on DigiDoc-It Bioimaging
system from UVP, Inc. (Upland, CA). For the same, TC-312R Fixed-Intensity UV
Transilluminator from Spectroline ultraviolet products and an Olympus C-3040 zoom
digital camera were used.

Spectrafuge

16M benchtop centrifuge and 21 IDS

Incubator/Shaker were purchased from Labnet International, Inc. (Edison, NJ). Petri
dishes were purchased from Nalgene Labware (Rochester, NY).
BL21 (DE3) pLysS competent cells for protein expression were purchased from
Stratagene (La Jolla, CA). Antibiotics viz. ampicillin and chloramphenicol were obtained
from Bio-world (Dublin, OH) and Calbiochem (San Diego, CA) respectively. All other
chemicals involved in the protein expression, detection and purification were bought
from Sigma Aldrich (St. Louis, MO).
Pre-made resolving and stacking buffers for doing SDS-PAGE experiments were
purchased from National Diagnostics (Atlanta, GA). All SDS-PAGE experiments
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performed were on Dual vertical mini-gel system from Cole-Parmer (Vemon Hills, IL).
The resulting gels were visualized on TW-26 White Light Transilluminator and
photographed by Olympus C-3040 zoom digital camera. Lab-line 3527 orbital
environmental shaker was used for bacterial cell growth. The cell growth was monitored
on UV-2100 spectrophotometer from Unico (Dayton, NJ). Penta-His HRP conjugate kit
and the nitrocellulose membrane for the dot blotting procedure were purchased from
Qiagen (Valencia, CA) and Bio-Rad laboratories (Hercules, CA) respectively.
Cell lysis experiments were performed using Sonicator 3000 from Misonix, Inc
(Farmingdale, NY). The HisTrap HP column and the AKTA prime system used for the
histidine-tagged purification of the C2 domain were purchased from GE Healthcare
(Piscataway, NJ).

Dialysis membranes of 6-8 kDa MWCO were purchased from

Spectrum laboratories (USA). Centricon filter devices of 10 kDa MWCO were purchased
from Millipore (USA). Agarose, Tris, and glycerol were from Bio-world (USA). 8M
guanidine hydrochloride (GuHCl) and 8M urea solutions used in CD titration
experiments were from Fluka (Switzerland). All other chemicals were from SigmaAldrich (USA).
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B .l. Agarose Gel Electrophoresis (X% w/v)
1. Take ‘X ’ g of agarose and dissolve it in 100ml of IX TBE buffer in an
Erlenmeyer flask.
2. Heat the flask in a microwave oven until it begins to boil. Mix the solution well
by shaking the flask at this point.
3. Now add 0.5/xl of lOmg/ml ethidium bromide solution to the flask, mix well and
continue boiling for another 30 seconds.
4. Take out the flask from the oven and allow the solution to cool for 5 minutes.
5. Now pour the solution into the casting tray and place the well-comb in its
position. Wait for 45 minutes for the gel to be cast and then load the samples into
different lanes.
6. Pour IX TBE buffer into the gel tank well enough to cover the surface of the
gel.
7. Now connect the terminals to the power supply making sure that the negative
terminal is on the side of gel lanes.
8. Rim the gel at 80 V for about an hour until the dye front has reached 70% of the
length of the gel.
9. Turn off the power supply and visualize the DNA bands present on the gel under
a UV Transilluminator.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

124

B.2. PCR Gel Extraction
1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel.
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume
of gel (lOOmg-100/d).
3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To
help dissolve gel, mix by vortexing the tube every 2-3 min during the incubation.
4. After the gel slice has dissolved completely, check that the color of the mixture is
yellow. If the color is orange or violet, add 10/d of 3M sodium acetate, pH 5.0,
and mix. The color of the mixture will turn to yellow.
5. Add 1 gel volume of isopropanol to the sample and mix.
6. Place a spin column in a provided 2ml collection tube.
7. To bind DNA, apply the sample to the column, and centrifuge for 1 min.
8. Discard flow-through and place column back in the same collection tube.
9. Add 0.5 ml o f Buffer QG to column and centrifuge for 1 min.
10. To was, add 0.75 ml of Buffer PE to column and centrifuge for 1 min.
11. Discard the flow-through and centrifuge the column for an additional 1 min at
13,000 rpm.
12. Place the column into a clean 1.5 ml microcentrifuge tube.
13. To elute DNA, add 50 /d of Buffer EB or H20 to the center of the membrane and
centrifuge the column for 1 min. For increased DNA concentration, add 30 /d of
elution buffer to the center of the membrane, let the column stand for 1 min, and
then centrifuge for 1 min.
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B.3. PCR Purification
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix.
2. Place a spin column in a provided 2 ml collection tube.
3. To bind DNA, apply the sample to the column and centrifuge for 30-60 sec.
4. Discard flow-through. Place the column back into the same tube.
5. To wash, add 0.75 ml Buffer PE to the column and centrifuge for 30-60 sec.
6. Discard flow-through and place the column back in the same tube. Centrifuge for
an additional 1 min.
7. Place the column in a clean 1.5 ml microcentrifuge tube.
8. To elute DNA, add 50 fi\ Buffer EB or H2 O to the center of the membrane and
centrifuge the column for 1 min. For increased DNA concentration, add 30 fi\ of
elution buffer to the center of the membrane, let the column stand for 1 min, and
then centrifuge.
B.4. Preparation of LB Agar Plates
1. Add 3.56 g of LB agar to 100ml of DI water in a bottle and shake it well.
2. Autoclave the bottle for 15 minutes.
3. Take the bottle out of the autoclave machine and swirl the bottle gently.
4. Allow the solution to cool to around 55°C. Then add required amount of
antibiotic/ antibiotics to the solution and mix it by shaking.
5. Then pour the solution in small amounts onto sterile plates/dishes. Tilt the plates
thereafter so that the solution covers the entire surface of the plates/dishes.
6. Leave the plates at room temperature for about 15 min to solidify. Then, wrap
them in aluminum foil and store at +4°C.
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B.5. Preparation of LB Broth
1. Dissolve 20.6 g of LB Broth EZmix in 1 liter o f DI water in a bottle.
2. Autoclave the bottle for 15 minutes.
3. Take out the bottle and allow it to cool to room temperature.
4. Store the broth at +4°C.
B.6. Transformation of XL2-BIue Ultracompetent Cells
1. Pre-chill two 14-ml falcon polypropylene round-bottom tubes on ice (One tube is
for the experimental transformation and the other for the pUC 18 control). Preheat
NZY+ broth to 42°C.
2. Thaw the ultracompetent cells on ice. When thawed, gently mix and aliquot 100
pel o f cells into each o f the two pre-chilled tubes.
3. Add 2 /il of the jS-mercaptoethanol provided with this kit to each aliquot of cells.
4. Swirl the tubes gently. Incubate the cells on ice for 10 min, swirling gently every
2 min.
5. Add 0.1-50 ng o f the experimental DNA to one aliquot of cells, in a l-/d volume
for maximum efficiency. Dilute the pUC 18 control DNA 1:10 with sterile DI
water; then add 1 fi\ o f the diluted pUC 18 DNA to the other aliquot of cells.
6. Swirl the tubes gently, and then incubate the tubes on ice for 30 min.
7. Heat-pulse the tubes in a 42°C water bath for 30 sec. The duration of the heat
pulse is critical for maximum efficiency.
8. Incubate the tubes on ice for 2 min.
9. Add 0.9 ml of preheated (42°C) NZY+ broth and incubate the tubes at 37°C for 1
hour with shaking at 225-250 rpm.
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10. Plate about 200 /xl of the transformation mixture on LB agar plates containing the
appropriate antibiotic. For the pUC 18 control transformation, plate 5 //I o f the
transformation on LB-ampicillin agar plates.
11. Incubate the plates at 37°C overnight and inspect for colonies thereafter.
B.7. Plasmid Extraction bv Minipreps Kit
1. Pellet 1-3 ml of cell culture by centrifugation for 1-2 min at 10,000 x g in a
microcentrifuge. Pour off the supernatant and blot the tube upside-down on a
paper towel to remove excess media.
2. Completely resuspend the cell pellet in 200 jul of cell resuspension solution.
Transfer the cells to a 1.5ml microcentrifuge tube if necessary.
3. Add 200 jul o f cell lysis solution and mix by inverting the tube 4 times. The cell
suspension should clear immediately.
4. Add 200 [i\ of neutralization solution and mix by inverting the tube 4 times.
5. Centrifuge the lysate at 10,000 x g in a microcentrifuge for 5 minutes. If a pellet
has not formed by the end of the centrifugation, centrifuge an additional 15 min.
6. For each minipreps, prepare one minicolumn. Remove the plunger from a 3ml
disposable syringe and set it aside. Attach the syringe barrel to the Luer-Lok
extension of the minicolumn and pipet 1 ml of the resuspended resin into the
barrel. (If crystals or aggregates are present, dissolve by warming the resin to 2537°C for 10 minutes. Cool to 30°C before use.)
7. Carefully remove all of the cleared lysate from each miniprep (supernatant from
step 5) and transfer it to the barrel of the minicolumn/ syringe assembly
containing the resin.
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8. Carefully insert the syringe plunger and gently push the slurry into the
minicolumn.
9. Detach the syringe from the minicolumn and remove the plunger from the syringe
barrel. Reattach the syringe barrel to the minicolumn. Pipet 2 ml of column wash
solution into the barrel of the minicolumn/ syringe assembly. Insert the plunger
into the syringe and gently push the column wash solution through the
minicolumn.
10. Remove the syringe and transfer the minicolumn to a 1.5 ml microcentrifuge tube.
Centrifuge the minicolumn at 10,000 x g in a microcentrifuge for 2 minutes to dry
the resin.
11. Transfer the minicolumn to a new 1.5 ml microcentrifuge tube. Add 50 pi of
nuclease-free water to the minicolumn and wait 1 minute. Centrifuge at 10,000 x
g in a microcentrifuge for 20 sec to elute the DNA.
B.8. SDS-PAGE (12%)
1. Initially the two glass plates of the dual vertical mini-gel system are thoroughly
washed and cleaned.
2. The silicone gasket is secured around one of the plates, and spring clamps are
used to hold the two plates against each other, providing a leakproof seal.
3. Now, 5ml of 12% resolving gel is prepared by mixing the following components:
2ml of Protogel solution, 0.325ml of 4x resolving buffer, 50pl of 10% (w/v) APS,
5 pi o f TEMED and 2.615ml of DI water.
4. Then, the resulting solution is degassed and poured onto the space between the
two plates and is allowed to set for about 45 minutes.
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5. Now, 1.6ml of 4% stacking gel is prepared by mixing the following components:
0.208 ml o f Protogel solution, 0.4 ml of 4x stacking buffer, 16 pi o f 10% (w/v)
APS, 1.6 pi of TEMED and 0.976 pi of DI water.
6. Then the resulting solution is degassed and poured on the top of the resolving gel.
At the same time, a Teflon comb is placed on the top of the gel to make wells in
it.
7.

Then the gel is allowed to set for about 30 minutes.

8. After 30 minutes, the samples are loaded into the wells of the gel and the gel is
run at 200V, 50mA for 45 minutes.
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Table C .l. Codon usage table for Escherichia Coli K12 strain
Triplet Amino
acid
F
UUU
F
UUC
L
UUA
L
UUG
L
cuu
L
cue
L
CUA
L
CUG
I
AUU
I
AUC
I
AUA
M
AUG
V
GUU
V
GUC
GUA
V
V
GUG
s
ucu
s
ucc
UCA
s
s
UCG
p
ecu
p
ccc
p
CCA
p
CCG
T
ACU
T
ACC
T
ACA
T
ACG
A
GCU
A
GCC
A
GCA
A
GCG

Fraction
0.57
0.43
0.13
0.13
0.10
0.10
0.04
0.50
0.51
0.42
0.07
1.00
0.26
0.22
0.15
0.37
0.15
0.15
0.12
0.15
0.16
0.12
0.19
0.52
0.17
0.44
0.13
0.27
0.16
0.27
0.21
0.36

Frequency:
per thousand
22.4
16.6
13.9
13.7
11.0
11.0
3.9
52.8
30.4
25.0
4.3
27.8
18.4
15.2
10.9
26.2
8.5
8.6
7.1
8.9
7.0
5.5
8.5
23.3
8.9
23.4
7.0
14.4
15.3
25.5
20.3
33.7

Triplet
UAU
UAC
UAA
UAG
CAU
CAC
CAA
CAG
AAU
AAC
AAA
AAG
GAU
GAC
GAA
GAG
UGU
UGC
UGA
UGG
CGU
CGC
CGA
CGG
AGU
AGC
AGA
AGG
GGU
GGC
GGA
GGG

Amino
acid
Y
Y
*
*
H
H

Q
Q
N
N
K
K
D
D
E
E
C
C
*

w
R
R
R
R
S
S
R
R
G
G
G
G

Fraction
0.57
0.43
0.64
0.07
0.57
0.43
0.35
0.65
0.45
0.55
0.77
0.23
0.63
0.37
0.69
0.31
0.45
0.55
0.29
1.00
0.38
0.40
0.06
0.10
0.15
0.28
0.04
0.02
0.34
0.40
0.11
0.15
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Frequency:
per thousand
16.3
12.3
2.0
0.2
12.9
9.7
15.5
28.8
17.6
21.7
33.6
10.2
32.2
19.1
39.6
17.8
5.2
6.4
0.9
15.3
21.0
22.0
3.5
5.4
8.7
16.0
2.1
1.2
24.9
29.4
7.9
11.0
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OLIGO CALCULATIONS
(1) Molecular weight of an oligonucleotide is given by
M.W= [312.21 X A ’s] + [289.18 X C’s] + [329.21 X G ’s] + [304.21 X T ’s] - 62 Da.
(2) Extinction coefficient o f an oligonucleotide is given by
E= [16,000 X A ’s] + [12,000 X G’s] + [7,000 X C’s] + [9600 X T’s]
(3) Quantity of H2 O needed in ml to dissolve an oligo is given by
Q= [O.D of the oligo at 260 nm] / [EX Molar concentration needed for the oligo]
Where ‘E’ is the extinction coefficient of the oligo.
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